covid 19 ppt presentation for students 2022

Got any suggestions?

We want to hear from you! Send us a message and help improve Slidesgo

Top searches

Trending searches

10 templates

hispanic heritage month

21 templates

indigenous canada

46 templates

49 templates

mid autumn festival

18 templates

suicide prevention

9 templates

Coronavirus Presentation templates

Raise awareness about one of the hottest topics of the 21st century by downloading and editing our free ppt templates and google slides themes about coronavirus..

• Calendar & Weather
• Infographics
• Marketing Plan
• Project Proposal
• Social Media
• Thesis Defense
• Black & White
• Craft & Notebook
• Floral & Plants
• Illustration
• Interactive & Animated
• Professional
• Instagram Post
• Instagram Stories

It seems that you like this template!

Register for free and start downloading now

Omicron covid-19 variant clinical case.

A new variant of COVID-19 has been notified by the World Health Organization and has been named "the Omicron variant". Questions and doubts start to arise and to solve them, there is no better idea than a clinical case with real examples to illustrate any doubt you may have. For...

Premium template

Unlock this template and gain unlimited access

Flu vs. COVID-19 Infographics

How to tell the difference between the flu and other diseases such as COVID-19? Some of their symptoms are similar, so we think a lot of healthcare workers will agree that people should be informed about this. Help patients or society in general by using these editable infographics. The variety...

Medicine and Healthcare Thesis Defense: Is Coronavirus Human-Made?

Download the Medicine and Healthcare Thesis Defense: Is Coronavirus Human-Made? presentation for PowerPoint or Google Slides. Congratulations, you have finally finished your research and made it to the end of your thesis! But now comes the big moment: the thesis defense. You want to make sure you showcase your research...

Stop The Virus! Distance Learning Escape Room

If you are a fan of escape rooms you will love this template that we have created in Slidesgo. It is inspired by these games and features a virus that you have to escape from. The design is creative, with purple background, fun illustrations and sans serif typography. Go solving...

COVID-19 Vaccine Breakthrough

Aren't you tired of COVID-19? Great news: vaccines are already here! Use this new editable template to tell your audience all the latest discoveries on the matter. Since blue is the color of safety, we've used it to set the right atmosphere. We've used other resources, such as illustrations of...

COVID-19 Outbreak Thesis

Several fields of study can benefit from interesting dissertations on how COVID-19 has spread all around the world. Your thesis is about this matter and you need to defend it in front of the assessment committee? Use this presentation during your speech and have your data on the screen while...

COVID-19 Vaccine Breakthrough: Case Investigation and Reporting

The COVID-19 vaccine has improved the pandemic situation. We are gradually returning to our pre-COVID-19 lifestyle. All this has been achieved thanks to the enormous efforts of the scientific community, which has not rested until a remedy has been found. However, new variants of COVID-19 continue to emerge and we...

COVID-19 Explained for Middle School

The pandemic has completely changed the way we live. The youngest have had to adapt without understanding what was going on. If you want to make COVID-19 understandable for your middle school students, we recommend using this editable template from Slidesgo. With it you can explain the symptoms, prevention measures,...

COVID-19 High School Lesson

It's true that COVID-19 has been around for almost a year now, but it's never too late to explain all about this virus and the prevention measures. This new template will be useful for high schools, as it's been designed with an educational purpose in mind. With a color palette...

Norwalk Virus Clinical Case

The best way to understand a disease is through a clinical case. Your knowledge about Norwalk virus, which causes acute gastroenteritis, occurs in outbreaks and is easily transmitted, will be key to prevent it. And this template, with its modern, yet professional and functional design, will be your best ally...

Medicine and Healthcare Thesis: A Scientific Explanation of COVID-19 and its Epidemiology

Download the Medicine and Healthcare Thesis: A Scientific Explanation of COVID-19 and its Epidemiology presentation for PowerPoint or Google Slides. Taking care of yourself and of those around you is key! By learning about various illnesses and how they are spread, people can get a better understanding of them and...

National Influenza Vaccination Week

National Influenza Vaccination Week is a week in December when the importance of getting vaccinated against the flu is emphasized, especially for older people and those who are at more risk for any medical condition. Most people get through the flu just fine, but it can also have dire consequences....

Immunology Breakthrough

The scientific world is continuously making strides in medical research, particularly in the field of immunology. Highlight these achievements with a Google Slides and PowerPoint presentation! Designed with clear blue hues, this template offers a professional and compelling way to share your groundbreaking research, data findings, and innovative treatments. Fully...

Infection by Microorganisms Case Report

Download the "Infection by Microorganisms Case Report" presentation for PowerPoint or Google Slides. A clinical case is more than just a set of symptoms and a diagnosis. It is a unique story of a patient, their experiences, and their journey towards healing. Each case is an opportunity for healthcare professionals...

Create your presentation Create personalized presentation content

Writing tone, number of slides, immunology - bachelor of science in human biology.

Download the "Immunology - Bachelor of Science in Human Biology" presentation for PowerPoint or Google Slides. As university curricula increasingly incorporate digital tools and platforms, this template has been designed to integrate with presentation software, online learning management systems, or referencing software, enhancing the overall efficiency and effectiveness of student...

Infectious Diseases Notebook

Download the Infectious Diseases Notebook presentation for PowerPoint or Google Slides. Taking care of yourself and of those around you is key! By learning about various illnesses and how they are spread, people can get a better understanding of them and make informed decisions about eating, exercise, and seeking medical...

Rotavirus Infection Breakthrough

Download the Rotavirus Infection Breakthrough presentation for PowerPoint or Google Slides.Treating diseases involves a lot of prior research and clinical trials. But whenever there’s a new discovery, a revolutionary finding that opens the door to new treatments, vaccines or ways to prevent illnesses, it’s great news. Should there be a...

Arbovirus Infections

Download the Arbovirus Infections presentation for PowerPoint or Google Slides. This incredible template is designed to help you create your own marketing plan that is sure to impress your entire team. Using this amazing tool, you'll be able to analyze your target audience, assess your competitors, map out your messaging...

• Page 1 of 10

Register for free and start editing online

Unsupported browser

This site was designed for modern browsers and tested with Internet Explorer version 10 and later.

It may not look or work correctly on your browser.

15 Best Free Covid Coronavirus & Virus PowerPoint PPT Templates 2024

Whether you need to make a Covid-related or any other medical presentation, one thing is certain. It’s much faster to start with a coronavirus PowerPoint template than trying to do it from scratch. 

Luckily, there are plenty of free and premium Covid and virus-themed PPT templates available online that you can use as a starting point. 

The Best Source for COVID Coronavirus and Virus PowerPoint Templates (With Unlimited Use)

Envato Elements is the best place to find premium coronavirus, Covid, and virus PowerPoint templates with professional designs. Envato Elements is a subscription-based marketplace. It gives you access to thousands of creative assets — for a single monthly fee:

• premium PowerPoint templates for all your presentation needs
• stock photos and royalty-free music that you can use in your presentations
• fonts, icons, and more to customize your presentation

Explore Virus PowerPoint Templates Now

Envato Elements gives you the best bang for your buck if you need PowerPoint templates and other design assets regularly. Unlike our premium templates, free PowerPoint designs often lack features and customization options.

Top 5 Premium Covid and Coronavirus PowerPoint Templates From Envato Elements for 2024

Before we show you the best free PowerPoint templates with virus themes, here are the top premium coronavirus PowerPoint templates from Envato Elements:

1. Delta Corona Virus PowerPoint Template

First, we've got the Delta Corona Virus PowerPoint template with a modern and clean design. This Covid slides template features 80+ slides. They've got all the necessary content ideas for you to create an engaging presentation.

The template also comes with handmade infographic elements. It was designed in HD resolution and comes in dark and light versions.

2. Covid-19 Virus - Medical PowerPoint Template

The Covid-19 is a medical PowerPoint template with more than 70 unique and modern slides. This Covid presentation template has a gorgeous duotone color scheme, but you can easily customize it to match your brand. You’ll also find unique mockup devices, image placeholders, infographic elements, and more. The template comes in widescreen resolution. 

3. Covirus - Disease & Virus PowerPoint Template

Here’s a unique and trendy Covid and virus PowerPoint template that'll make creating your presentation a breeze. The template comes with 33 unique slides. You can customize colors, fonts, and even the slide layout to create the perfect presentation. You’ll also find image and media placeholders, vector-based icons, and mockup devices. 

4. Secure Virus 19 Medical PowerPoint Template

This coronavirus PPT has twenty-five unique slides. It can help you deliver a comprehensive presentation. Finding the right color scheme for your business won't be a problem. Included are over ninety color schemes that are fully customizable.

You'll find much-needed infographics, vectors, and charts as well. Download this complete Covid PowerPoint template.

5. Covid Virus - Medical PowerPoint Template

This Covid presentation template gives you the power to create an eye-catching presentation. Included are forty-six slides that feature modern designs. Many graphics are included to help you deliver a compelling presentation to your audience. Free web fonts are included, and you can drag and drop in images of your choice to any slide.

The premium templates mentioned are some of the highest quality available. If you're on a budget, you may not be able to afford the premium templates. In this next section, we'll go over the top free PowerPoint templates virus. 

15 Top Free Covid Coronavirus & Virus PowerPoint Templates to Download

Before looking for a free Covid PowerPoint template on the web, check Envato's free offerings first. Try out various premium template files (not always PowerPoint files) at no cost to you.

Here's the deal: 

With that in mind, here are the best free coronavirus and virus PowerPoint templates that you can find and download online for your presentation: 

1. Free Social Distance PowerPoint Template

With the help of this coronavirus PowerPoint template for free, you’ll have no problem explaining social distancing rules. The Covid PowerPoint template includes four pre-designed slides.

2. Medicine Health Care PowerPoint Templates

Try this medicine and healthcare PowerPoint template if you’re looking for a modern template. Use it to present all the necessary information about Coronavirus or any other medical emergency.

3. Medical Laboratory PowerPoint Templates

Here’s a free template virus that would be perfect for any type of virus research presentation. The template comes with individual slides as well as section covers. It includes 25 slides.

4. Coronavirus Pandemic PowerPoint Templates

Share important findings and information about Coronavirus or any other virus with this modern template. It comes with three master slides that you can customize.

5. Covid-19 Coronavirus PowerPoint Templates  

This free Covid PowerPoint template has a dark green background with virus icons. Use it to quickly create a presentation. The template comes with three master slides designed in several resolutions.

6. Infection PowerPoint Templates

Use this fun infection PowerPoint template to create a presentation about virus research or to provide more information about a specific virus. The Coronavirus PPT includes three master slides that you can duplicate to create your presentation.

7. Free COVID-19 Vaccine PowerPoint Template

With the help of this free PowerPoint template with a virus theme, you can easily share all the information people need to know about Covid-19 vaccines. The Covid vaccine theme PowerPoint comes with four slides.

8. Free COVID-19 Presentation Template

Use this Covid presentation template to create a presentation that shares information about the virus and how to fight it. The template has four master slides that you can copy as many times as you need.

9. Free Covid PowerPoint Template

Here’s a minimal and simple COVID PowerPoint template. It features an image that shows the virus spreading all over the world. It also contains four master Covid PowerPoint slides that you can copy for your presentation. 

10. Free COVID PowerPoint Background

Consider this free COVID PowerPoint background for your presentation. It features an image of a word game spelling out coronavirus, pandemic, and virus. 

11. Medical Illustrated. Free PowerPoint Template & Google Slides Theme

Here’s another minimal and clean PowerPoint template. Use it for any type of medical presentation. The Covid presentation template comes with 25 slides.

12. Blue Medical. Free PowerPoint Template & Google Slides Theme

The blue color in this medical and virus PowerPoint template conveys professionalism. It comes with 25 covid PowerPoint slides.

13. Medical Virus. Free PowerPoint Template & Google Slides Theme

This coronavirus PowerPoint template for free can be used for sharing information about the virus and how to prevent the spread. The template comes with 25 slides that you can duplicate, re-order, and delete as you see fit.

14. Free COVID-19 Health System Capacity Curve PowerPoint

Use this free Covid-19 PowerPoint template to showcase the virus's effect on the health system capacity. The template includes several different slide variations.

15. Coronavirus PowerPoint Template

Use this coronavirus PowerPoint template for free to create informative presentations about coronavirus measures, treatments, and protection. It comes with several slides, including section cover and agenda slides. 

How to Make a Coronavirus Presentation in PowerPoint

1. Choose the Right Slides

Not all the slides in the template will work for your presentation. Go through each slide and pick the ones that pertain to your presentation. For the slides, you don't want to use, left-click the slide and choose Delete Slide .

2. Add In Your Content

Now it's time to add in your presentation's content. Have a document open with all the text you want to use for each slide. Then copy and paste the text to each slide.

Each slide has text placeholders. Double-click the placeholder text and select all the text. You can then paste in your text.

3. Add In Your Images

Next, we'll add in our images to make the presentation more visually appealing. Just like the text, there are also image placeholders. To add in your images, click the image icon on each slide. Your computer files pop up. Choose the image you want to add. 

4. Add in Animations

To help add professional polish to your presentation, we'll add in animations. Choose the top menu header that says Animations . From there, choose the animation that you want to have on your slides. To see what each animation looks like, choose the Preview button on the far left side of the menu.

5. Proofread Your Presentation

Often this step is skipped. We get caught up in making our design look perfect and forget to proofread our presentation. Having grammatical errors and misspelled words is the quickest way to make your presentation look unprofessional. Take the time to go over every slide in your presentation before calling it done.

5 Quick Tips To Make Virus-Themed PPT Presentations in 2024

You’ve just seen the best free and premium coronavirus slideshow templates. Now, here are a few quarantine PowerPoint ideas that'll help you design a standout presentation: 

1. Stand Out With Custom Icons and Illustrations

Custom icons and illustrations make your presentation more memorable. Not to mention, they'll make your presentation stand out. The Covid-19 PowerPoint template features modern custom vector graphics that you can use as inspiration.

2. Keep the Text to a Minimum

Don’t overwhelm your audience by adding a lot of text on your slides. This can cause them to read the slide before you’re done presenting it and they may become disengaged. Instead, keep the text to a minimum of one to three bullet points per slide.

3. Use a Professional Color Scheme

You don’t have to shy away from color in your presentation. Make sure that your color scheme is professional and doesn’t contain any clashing colors. You can draw inspiration from this modern Coronavirus Medical PowerPoint template from Envato Elements.

4. Use Charts for Complex Data and Statistics

If you've got a lot of complex data and statistics, consider using charts and infographic elements to represent them. This will make it easier for your audience to understand and absorb the information.

5. Customize the Slides With Your Photos

Using stock photos is a great way to make your presentation more memorable. But you can achieve an even better effect by including photos of you, your team, and your employees. A template like the Corona Virus PowerPoint Template has plenty of image placeholders for you to use.

Discover More Top PowerPoint Template Designs

If you want to see even more PowerPoint template examples or if you need to create a different type of presentation, look at the following template roundups:

Common PowerPoint Questions Answered (FAQ)

If you're creating a Coronavirus PPT presentation and you're not familiar with PowerPoint, you may have some questions. We've got you covered! Here are some common PowerPoint questions and their answers:

1. I'm New to PowerPoint, What Should I Know?

PowerPoint is a powerhouse presentation software. But learning just the basics of the software enables you to create a complete presentation. Check out our ultimate PowerPoint guide to learn these basics.

2. How Should I Design My Slides?

The visual hierarchy of the slides dictates the design. The arrangement of the elements on your page and how they're placed has the biggest effect on what your audience remembers. Your slide's colors, typography, and images used are major contributors to the design of your slides. 

3. Can I Collaborate on One Presentation?

PowerPoint Online makes collaboration possible. This makes it easy to delegate separate tasks that need to be completed for the presentation. For an in-depth guide on how to collaborate as a team, view the article below.

4. What Colors Should I Use In My Coronavirus PPT?

The colors that work well are blue and red. Red helps highlight the urgency and danger of the virus and blue helps build trust with your audience. If your business has a set of brand colors, then you can use these colors as well. 

5. Can I Print Out My Slides?

Yes, you can! Print out your slides may be necessary depending on where you're presenting. Check out the tutorial below for a complete guide on how to print out your slides.

Learn More About Making Great PowerPoint Presentations in 2024

The tips we shared above are only a small selection of what makes a great presentation. If you want to learn more about designing and writing great PowerPoint presentations , check out the tutorials below: 

Create a Coronavirus Presentation Quickly With Templates

If you need to create a presentation about Coronavirus or any other type of medical presentation, there's no shortage of free PowerPoint templates with a virus theme to choose from. But, if you want to make your presentation look more unique, don’t forget to check out premium templates. 

Stop by Envato Elements if you know you’ll be needing PowerPoint templates and other creative assets on the regular or if you've got multiple brands to promote. 

Editorial Note: This post has been updated with contributions from Daniel Strongin . Daniel is a freelance instructor for Envato Tuts+.

• Biochemistry and Molecular Biology
• Biostatistics
• Environmental Health and Engineering
• Epidemiology
• Health Policy and Management
• Health, Behavior and Society
• International Health
• Mental Health
• Molecular Microbiology and Immunology
• Population, Family and Reproductive Health
• Program Finder
• Admissions Services
• Course Directory
• Academic Calendar
• Hybrid Campus
• Lecture Series
• Convocation
• Strategy and Development
• Implementation and Impact
• Integrity and Oversight
• In the School
• In the Field
• In Baltimore
• Resources for Practitioners
• Articles & News Releases
• In The News
• Statements & Announcements
• At a Glance
• Student Life
• Strategic Priorities
• Inclusion, Diversity, Anti-Racism, and Equity (IDARE)
• What is Public Health?

COVID-19 in 2022: A Year-End Wrap-Up

At the conclusion of the pandemic’s third year, a look back—and forward.

Jackie Powder

Omicron overstayed its welcome. At-home COVID-19 testing was routine. The bivalent booster arrived.

The past 12 months also saw the U.S. surpass more than a million total COVID deaths, vaccine authorizations for very young children , and a year-end tripledemic . 

As year three of the COVID-19 era draws to a close, we asked some of the School’s pandemic experts to weigh in on the good, the bad, and the unknown of COVID-19 in 2022, and share their greatest hope—COVID-wise—for 2023. 

In 2022, COVID-19 illness was less severe and less deadly compared to 2020 and 2021, and no new variant has emerged with the capacity to fuel a major wave of cases. Contributing factors to these positive developments: 

• Unprecedented advances in vaccine technology that allow for rapid updates to protect against new strains.
• A more effective treatment and prevention toolbox of vaccines and boosters, oral antivirals, and home test kits.
• Growing population immunity to the virus.

“Mortality and illness from COVID-19 now looks a lot more like that of influenza, concentrated in older age groups and on the same order of magnitude, and there is hope that as our immune systems see this virus even more, illness will continue to get milder,” says Epidemiology professor David Dowdy, MD, PhD ’08, ScM ’02 . 

COVID became less of a disruption in our lives, making it possible to resume pre-pandemic activities like travel, attending large events, and going to school in person and unmasked.  

“We have built enough immunity to COVID to allow life to return to normal in many ways without huge surges in the number of deaths any longer,” says Epidemiology professor Gypsyamber D’Souza, PhD ’07, MPH, MS . 

Amesh Adalja, MD , senior scholar with the Center for Health Security , maintains that “people have, for the most part, learned to risk calculate and navigate a world with an unavoidable new virus.” 

This year has also demonstrated that COVID has permanently altered how and where we work.

“There have been societal changes in work-from-home and hybrid-work availability that are positive for many individuals,” says D’Souza. 

In January and February, the U.S. was in the midst of the initial omicron wave. (The variant emerged in late 2021.) “At its peak, the wave involved the highest weekly number of [COVID-19] cases and nearly the highest weekly number of deaths of the entire pandemic,” says Dowdy. 

“Neither vaccination nor having had COVID reduced chances of reinfection as much as we would like, and we will continue to see high transmission this winter,” says D’Souza. “Although risk of severe illness is much lower, many people have symptoms that keep them in bed for days feeling quite unwell.”

Also in the negative column: continued COVID misinformation, particularly around vaccines, with “follow-on consequences for regular childhood vaccinations,” says Tara Kirk Sell, PhD, MA , senior scholar with the Center for Health Security; underutilization of the antiviral medication Paxlovid; clear evidence of pandemic fallout in other aspects of our lives and in society as a whole, including increased rates of mental illness especially among adolescents, “higher levels of opioid overdose, [and] educational shortfalls,” Dowdy says. 

The Unknown

Experts agree that China’s relaxing of two years of zero-COVID policies tops their list of unknowns. Outbreaks are occurring across the country, and hospitals report being overwhelmed as COVID and flu collide.

Says Dowdy: “More than one-sixth of the world’s population lives in China. … We could see a huge wave of COVID-19 in the next few months, as levels of immunity there are much lower.”

Some other key questions and concerns: 

“Will public health departments be able to maintain the badly needed skills and expertise they were able to gain during the pandemic?” Sell asks. “Almost every public health department leader I’ve spoken to in the past few weeks is stressing about being able to keep staff.”  

D’Souza notes: “It’s unclear how well the new bivalent boosters protect against current strains—and since many people have had COVID this summer or fall, it’s unclear whether they would benefit from boosting. How long to wait after having had COVID before getting the booster is not well understood.” 

Another unknown, says Amesh Adalja, is “how COVID impacts the circulation of other respiratory viruses and overall mortality from pneumonia and influenza, over the long term.”

Hopes for 2023

Tara Kirk Sell: “I hope that COVID-19 will be relegated to a normal public health concern—something like how we work to protect people from flu, car accidents, suicides, heart disease. It probably won’t ever disappear, but it can be something we can manage going forward.”

Amesh Adalja: “Universal vaccines, better antivirals, new monoclonal antibodies, handling COVID like other respiratory viruses.” 

Gypsyamber D’Souza: “My hope is that most people feel their lives are back to normal and that there is less stress and concern about whether to be able to travel, see family and friends, and attend large gatherings.” 

David Dowdy: “My hope is that 2023 will be the year where we truly feel like our lives are getting back to normal. Life will never be completely the same, and we will be dealing with the aftermath of the pandemic for many years to come. But I hope that by the end of 2023, COVID-19 and its after-effects won’t even crack most people’s ‘top 10 problems in my life right now.’ That would be a huge public health success.” 

Jackie Powder is the assistant editor of Hopkins Bloomberg Public Health magazine.

• Keeping Track of COVID-19 Omicron Variants
• Bivalent Covid-19 Booster Updates
• 10 Reasons To Vaccinate Your 5 & Under Child for COVID-19 as Soon as Possible

Related Content

A ‘Critical Pathogen’: The Rise of Drug-Resistant Fungal Diseases

What to Know About the Updated COVID Vaccine for Fall, Winter 2024–25

Why We’re Still Waiting for a Pandemic Treaty

Why COVID Surges in the Summer

The Visible and Unseen Dangers Lurking in Floodwater

We use cookies on this website to enhance your experience. You can find out more about how we use cookies here

Preventing COVID-19: Refresher Presentations for Schools and Childcare Settings

Understanding how COVID-19 is transmitted and ensuring that proper public health measures are in place is important for preventing the spread of COVID-19 in schools and childcare settings. This presentation series provides those working in school and childcare settings a refresher about the public health practices that help prevent and control the spread of COVID-19. Implementing all recommended public health measures is important to help prevent the spread of COVID-19 in your facilities (i.e., no single measure should be relied on by itself).  Below you will find links to the recorded presentations as well as a downloadable copy of the presentation slides.

COVID-19 Transmission

An overview of how COVID-19 is spread, measures to reduce the risk of spread and implications for infection prevention and control (IPAC) in schools and child care settings.

• Duration: 9 min
• Updated 3 Sep 2021
• View the full transcript

Presentation

Hand Hygiene

Hand Hygiene: The Importance of Cleaning Hands

• Duration: 8 min

The role of cleaning your hands in preventing the spread of COVID-19 as well as review of the proper technique for cleaning your hands and hand care.

Physical Distancing

Environmental Cleaning

• Duration: 7 min

Considerations for cleaning and disinfecting surfaces in school and child care settings.

A Review of the Current Global Mpox Situation and the Public Health Approach to the Increase in Cases in Ontario

This PHO Rounds will provide a background on the different mpox clades including an epidemiological update on the mpox situation globally and in Ontario. We will highlight key updates on laboratory testing for clade Ib, the use of third-generation smallpox vaccine to prevent mpox infection, and review infection prevention and control measures.

Communications

[email protected]

• Media Centre

Don’t have a MyPHO account? Register Now

You must be logged in and have the correct access level to access this product.

Login or Register

COVID-19 lectures and seminars

Updated: Sept. 30, 2022

University of Washington faculty, staff and students have been sharing their COVID-19 expertise through online lectures and seminars, in addition to providing expert insight in the news .

You can watch recordings of past events below, as well as find additional events on the calendars for the Bothell , Seattle and Tacoma campuses.

Series archives | Past events

Series archives

Wednesdays: school of public health biweekly webinar.

School of Public Health Dean Hilary Godwin hosts a series of biweekly webinars designed to share the latest updates on the School’s and the UW’s response to the COVID-19 outbreak. The webinars are open to all UW faculty, staff and students, while guidance provided is for students, staff and faculty with primary affiliations in the School of Public Health.

The Whole U: COVID-19 virtual seminars

The Whole U has hosted a number of virtual seminars to help you stay informed and healthy during COVID-19. Watch videos from these events, which cover topics ranging from children’s well-being and mindful parenting to self-care and how to stay grounded during turbulent times.

2020: The Course

From a pandemic to economic fallout to a reckoning over race and policing in the United States, 2020 is sure to be remembered as a year of historic upheaval and change. The UW’s world-renowned scholars in the areas of history, sociology, education, law, environmental science — to name a few — can help place this tumultuous and chaotic time into a larger context and bring greater understanding. Students engaged in a series of talks, lectures and dialogues with over 20 faculty from across the University, and many of these presentations are now available for public viewing.

watch the videos

2021 events

Preparing for a post-covid future — implications for protecting the health of seniors.

The COVID-19 pandemic has wreaked havoc on everyone’s lives, and seniors were profoundly affected. What have we learned so far? How have we adjusted, and how can we best prepare to protect our health and safety as winter approaches?

Dr. Robin Fleming, assistant teaching professor at the University of Washington Bothell and board member of Northwest Neighbors Network, had a conversation with Dr. Vin Gupta, affiliate assistant professor of Health Metrics Sciences at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, about how the COVID-19 pandemic has changed the landscape of health care and public health communications — and the implications this has for seniors.

Mariner Mental Health Outcomes and Needs During COVID-19

The COVID-19 pandemic continues to have significant impacts on mariners and the global shipping industry. In addition to the direct health risks posed by COVID-19 infection, maritime personnel face additional physical and mental-health stressors from restrictions on crew changes, shore leave and repatriation of seafarers.

Dr. Marissa Baker is an assistant professor in the UW Department of Environmental & Occupational Health Sciences and program director of the industrial hygiene training program at the Northwest Center for Occupational Health and Safety. She is an affiliate faculty in the Harry Bridges Center for Labor Studies at UW. During the COVID-19 pandemic, she has been working closely with a variety of worker organizations, government and industry partners to characterize physical and mental health outcomes experienced by workers due to the pandemic, characterize their risk perceptions and needs and propose and evaluate interventions for safe work.

learn more 

Coexisting with COVID-19

The COVID-19 pandemic has proven to be more than just a threat to our health: it’s become a disruption of our way of life, affecting everything from supply chains, to the way we love, to what is considered essential work. How are we to think about and live amidst this “new normal”?

To answer this, the Graduate School’s Office of Public Lectures , in partnership with the Population Health Initiative , the Communication Leadership program within the Department of Communication, and many others, created “Coexisting with COVID-19.” Hosted by Hanson Hosein , the 30-minute livestream talks featured faculty members from across the UW.

watch the talks 

COVID-19 and Kids: Impacts, Uncertainties and the Role of Vaccines

The COVID-19 pandemic has profoundly affected every segment of society, including unique and widespread harms to children such as the closure of schools and the loss of nearly all group activities. Johns Hopkins University and the UW are convening clinical, scientific, regulatory and private sector leaders to discuss the effect of COVID-19 on youth and the role pediatric vaccines may play in the COVID-19 response. This virtual symposium will focus on several key areas:

• COVID-19’s broad effect on youths in the 5- to 12-year-old age range and their families
• The current state of play in youth vaccine development
• Ethical aspects of global vaccine scarcity and youth immunization

The first symposium in this series, Preserving the Scientific Integrity of Getting to COVID-19 Vaccines: From Clinical Trials to Public Allocation , is available to watch now.

more information

Law for the People — Introduction to Landlord/Tenant Law and the Washington Eviction Moratorium

In response to the COVID-19 pandemic and sustained global economic slowdown, the Washington State Legislature passed several new laws concerning landlord-tenant relations, including SB 5160 and HB 1236. Yet Washington’s residential housing situation was fraying well before the COVID pandemic. This presentation provides a broad survey of Washington evictions in the years before COVID-19, then provides an overview of SB 5160 and HB 1236’s increased tenant protections to get a sense of how residential tenancies will emerge from the COVID-19 pandemic.

May 12: COVID vaccines & variants — What you need to know to help end the pandemic

Over the past year, Vin Gupta, M.D., has become a familiar face as a COVID-19 medical contributor for MSNBC and NBC News, and he will be the featured speaker at the upcoming Next Generation Medicine webinar, presented by the UW School of Medicine – Gonzaga University Health Partnership. Dr. Gupta is an affiliate assistant professor of Health Metrics Sciences at the UW and a critical care pulmonologist who has been at the forefront of the COVID-19 pandemic since day one. In this webinar, he shared the latest information about the COVID-19 vaccines and their effectiveness against the virus variants first found in the U.K., South Africa and Brazil, and what we can do to help bring an end to the pandemic in our own communities. Dr. Gupta will help dispel myths, provide facts and address your concerns in a Q&A session.

LabMed Grand Rounds — COVID-19 vaccine trials: A year of progress

Lisa Jackson, MD, MPH, senior investigator with Kaiser Permanente Washington Health Research Institute will discuss: the progress of candidate COVID-19 vaccines from Phase 1 trials to Emergency Use Authorization; as-yet-unanswered questions about the vaccines now in routine use; next steps in vaccine development and implementation.

How to support your immune health and mental health during COVID-19

The COVID-19 pandemic has shed light on the importance of mental health and raised questions about how immune systems work. At How to Support Your Immune Health and Mental Health During COVID-19, Dr. Thuan Ong, a geriatric medicine specialist at UW Medicine, had a conversation with UW Medicine’s Dr. Mark Wener and Anne Browning, Ph.D., about how to care for your immune and mental health.

Mission possible — The vital role nurses play in the race to vaccinate

The University of Washington School of Nursing and Johns Hopkins University School of Nursing are proud to present a virtual symposium where leading experts will share their in-depth knowledge of the logistical, medical, and other details of the COVID-19 vaccination program. This is an opportunity for the community and nursing professionals to coordinate information and inquiries, advocate for vaccination, and influence how we implement the vaccination program.

watch the recording

The COVID-19 pandemic and the impacts of systemic racism

COVID-19 has shone a spotlight on how racism impacts the health and well-being of Black, Indigenous and People of Color across our county and country. While Public Health’s mission is to improve the health all members of our community, institutional racism has meant that BIPOC communities are significantly and disproportionately impacted by COVID-19 despite public health efforts. Patty Hayes, Director of Public Health — Seattle & King County, discusses the impact of the pandemic on BIPOC communities and what systemic changes need to be made now to avoid long-lasting impact.

 Social injustice and COVID-19 vaccines

What makes structural injustice structural? Building on her recent book, Structural Injustice with Madison Powers, Dr. Ruth Faden explores this question by examining the kinds of impacts, the kinds of social structures and the kinds of groups that matter on their theory of structural injustice. She then discusses how questions of equity and structural injustice are making their way (or not) in global and national plans for the allocation and prioritization of COVID-19 vaccines in the pandemic.

2020 events

Next generation medicine presents – making sense of the covid-19 vaccine.

The development of a vaccine to fight against SARS-CoV-2 is exciting news, but few of us understand what this means, beyond understanding it’s a possible barrier against COVID-19. How are vaccines developed and how do they work? Will all of the COVID vaccines be the same? How will we know if the vaccine is safe and effective? How often will we need to be vaccinated? Will there be enough vaccine for everyone? Dr. Deborah Fuller, vaccinologist and professor of microbiology at the University of Washington, discusses the answers to these questions and more. Dr. Fuller’s lab has been the site of development of a vaccine candidate since January 2020.

Contact tracing – Fighting COVID-19 while respecting privacy

Contact tracing is a critical tool in fighting the COVID-19 pandemic, enabling health officials to track and slow the disease’s spread. Mobile phones offer opportunities to improve the accuracy of contact tracing but come with risk of creating a new surveillance infrastructure. Join the College of Engineering for a talk about the benefits and drawbacks of contact tracing, its widespread use, and digital contact tracing methods being developed at the UW and Microsoft Research to protect the privacy of individuals.

Watch the recording

Protests for the soul of a nation – COVID-19, Black Lives Matter and election 2020

2020 is a year like we have never witnessed. A pandemic that exposed structural health inequalities was followed by the largest civil rights uprisings in American history against police violence and systemic racism. The sustained demonstrations and radical imagination of protesters have challenged and remade the relationship between government and citizens. Associate Professor of Political Science Megan Ming Francis discussed how we got to this urgent moment, the role organized protest can play in the upcoming election, and the future of a fair and robust democracy.

Creating a better normal – Improving population health for everyone

The pandemic has highlighted the racial, social and economic inequities that shape the health and well-being of all people in the United States and throughout the world. As we look forward to a post-COVID-19 world, how can we create a future in which we are all healthier — as individuals and as entire populations? How do we enhance the resilience of the environment we rely on? And how do we address the factors perpetuating the inequities that harm so many?

 COVID-19 – Is there an end in sight?

The UW School of Medicine – Gonzaga University Regional Partnership’s Next Generation Lecture series featured Dr. John Lynch, associate professor of medicine in the Division of Allergy and Infectious Diseases at the UW School of Medicine, and head of the UW Medicine COVID-19 Response Team. Dr. Lynch shared the latest information on the COVID-19 pandemic, including when we may see the first vaccines, improvements in testing and how long it could take to get the SARS-CoV-2 virus under control.

Healthy people, healthy planet: That’s population health

The COVID-19 pandemic has revealed how interconnected our health is with the health of those around us, as well as highlighting systemic inequities that affect the well-being of entire communities. Join Dr. Ali Mokdad, the UW’s chief strategy officer for population health, for an introduction to the UW’s work to advance population health and learn about the University’s quest for answers to some of today’s biggest health challenges.

Preserving the scientific integrity of getting to COVID-19 vaccines

Efforts to develop COVID-19 vaccines are well underway, and protecting the scientific integrity of the process is paramount. The trials must be – and must be seen to be – free of political interference, carried out with the highest scientific and ethical rigor, and allowed to proceed until the safety and efficacy of each candidate vaccine has been thoroughly assessed. The ultimate goal is global distribution of and equitable access to effective vaccines that can help slow, and eventually end, the pandemic.

October 6, the University of Washington and Johns Hopkins University brought together leading experts to explore these issues and put forward a concise plan for protecting the scientific integrity of these lifesaving efforts. This symposium featured insights from global leaders in vaccine science, health metrics, policy, regulation, and communications.

Finding your voice during the times of COVID

As part of the UW School of Nursing’s Nightingale Leadership Series, this event with Sue Birch, director of the Washington Health Care Authority, helps participants be an advocate and leader when responding to inquiries in times of crisis and find empowerment in speaking up.

Stand with The Facts – Community solutions to combat misinformation

With so much information being shared online and on social media during the pandemic and protests, how do we weed out the misinformation from the facts in our newsfeeds? Is it possible to improve access to reliable sources? What ways can we rethink information distribution to stop the spread of misinformation? And what kinds of local programs and services are communities creating to respond to today’s information overload? Join KUOW and the Center for an Informed Public for this online event, part of their Stand with the Facts series.

Stand with The Facts – How bots and trolls leverage a crisis

Many of us turn to social media to find real-time information, share resources and organize. But how do we know if there’s a real person behind the accounts on our feed? How have bots and trolls used global Black Lives Matter protests and a pandemic to create more division and uncertainty? Join KUOW and the Center for an Informed Public for this online event, part of their Stand with the Facts series.

Stand with the facts – Finding facts during a crisis

Since the start of the global pandemic and nationwide protests against racial injustices, there has been a flood of information online. As new information hits our news feeds daily, there’s still a lot of uncertainty around the virus and response to the protests. How does the unpredictable nature of the situation make us susceptible to consuming and potentially sharing misinformation? Join KUOW and the Center for an Informed Public for this online event, part of their Stand with the Facts series.

Stand with the facts – Big Tech and the fight against misinformation

There is more information shared on social media than any other time in history, and the information is not always factual. What can big tech companies like Facebook and Twitter do to regulate misinformation without infringing on users’ right to free speech? Will the government regulate these companies, and what would that look like? How will this help or hurt the coming elections? Join KUOW and the Center for an Informed Public for this online event, part of their Stand with the Facts series.

What the COVID-19 pandemic tells us about science in society – A conversation with Ed Yong and Liz Neeley

The COVID-19 pandemic has touched every part of our global society, putting science and scientists in the front seat as we navigate this crisis. The UW College of the Environment and School of Public Health hosted this live discussion with deans Lisa Graumlich and Hilary Godwin and special guests Liz Neeley, executive director of the Story Collider, and Ed Yong, staff writer covering science and the coronavirus for The Atlantic. This event was a special edition of Amplify, hosted by the College of the Environment, a series of conversations among faculty, staff, postdocs and graduate students from across the UW that explores the intersection of science and society, the role of science journalism and science communication and how to make sense of all the information and turn it in to action.

Husky alumni panel – Launching and navigating your career in uncertain times

UW Tacoma alumni from various class years, who graduated during economic downturns, life challenges or extreme circumstances, shared how they navigated their job search, networked, launched their careers and secured employment during uncertain times. They also shared how their work life has changed due to the current impact of COVID-19.

Leading an institution through an unprecedented crisis

By June, college leaders had worked quickly for more than three months to adapt to the COVID-19 crisis. They had to make countless short-term judgment calls while attempting to weigh longer-term ramifications. Despite looming uncertainty, colleges had to move forward and plan for the future. UW President Ana Mari Cauce, Oberlin College President Carmen Twillie Ambar, president of Oberlin College and California State University Chancellor Timothy P. White took part in a virtual roundtable hosted by The Chronicle of Higher Education focusing on fundamental changes to the role of the president and on leaders’ emerging insights into crisis management and campus communication.

Ambiguous loss – Grieving in the time of COVID-19

Life as we knew it just a few weeks ago has been completely turned upside down. That feeling you are feeling but can’t seem to describe may be grief. How do we recognize the signs and symptoms of grief and how do we cope? This webinar from the Forefront Suicide Prevention Center and the Northwest Mental Health Technology Transfer Center will give you an overview of what grief looks like at any time but especially during a time of ambiguous loss. We will talk about how to care for yourself and others in a time of uncertainty.

Next Generation Medicine Lecture – Wellness & resilience during COVID-19

During this challenging time of COVID-19, you may be experiencing stress, fear, grief and other complex emotions. Dr. Anne Browning, assistant dean for well-being with the UW School of Medicine and founding director of the UW Resilience Lab, will share ways to stay healthy and manage anxiety, and how to cope with the uncertainty of what’s to come. This free webinar is sponsored by the UW School of Medicine-Gonzaga University Regional Health Partnership.

COVID-19 and the mission of the U.S. public university

How have public universities responded to the COVID-19 pandemic? As university presidents look toward resuming in-person classes in the fall, what have they learned from the crisis, how will their institutions evolve as a result, and what might that mean for the future of higher education in America? President Ana Mari Cauce, Arizona State University President Michael Crow and Purdue University President Mitch Daniels will take part in a discussion hosted by the National Academies of Sciences, Engineering and Medicine.

The impact of COVID-19 on school mental health in Washington

The University of Washington School Mental Health Assessment, Research, & Training (SMART) Center – a collaboration between the UW School of Medicine and College of Education – presents the 2020 Virtual SMART Speaker Series. This third session features Washington state Superintendent Chris Reykdal to discuss how the pandemic is affecting young learners. Open to the public; advance registration required.

State policymaking in times of crisis

The UW Department of Political Science is offering this first virtual faculty panel examining the roles that state governments are and will be playing in addressing the numerous effects of the COVID-19 epidemic. Topics to be covered include state public health responses, safety-net policy variations and 2020 election administration.

Business recovery and reconstruction workshops

As owners of small- and medium-sized business are adjusting to economic changes wrought by the COVID-19 pandemic, faculty from the University of Washington Foster School of Business are offering a series of workshops to help companies pivot to new opportunities and position themselves for sustainable growth over the next two years. Each workshop will include both lectures from Foster School faculty and peer-to-peer discussions that will provide mutual support among business owners.

watch the recordings

Bioethics and Humanities Grand Rounds – COVID-19 series

The UW Department of Bioethics and Humanities is holding a special Bioethics Grand Rounds series about COVID-19, offered via Zoom. The four-part series aims to provide practicing health care workers from across disciplines the opportunity to reflect on difficult ethical questions that have arisen during the pandemic. The interactive sessions are intended for professionals across the greater Seattle area and WWAMI (Washington, Wyoming, Alaska, Montana and Idaho) region, regardless of association with University of Washington.

COVID-19 town hall

The COVID-19 pandemic and resulting economic crisis have upended lives and disrupted operations across the University of Washington. President Ana Mari Cauce hosted a virtual town hall on May 1 with a panel of UW leadership to address questions about how the COVID-19 pandemic has affected our community and what the future holds.

COVID-19 global conversations

Sharing knowledge in times of global crisis is part of the Henry M. Jackson School of International Studies’ mission. Take a virtual journey around the world in an occasional series of global conversations between Jackson School faculty in Seattle and experts in other countries to help make sense of the world in the time of COVID-19.

Exploring and understanding the COVID-19 pandemic

This six-seminar series provides a general overview of the COVID-19 pandemic. These weekly sessions are facilitated by UW faculty members who are coronavirus and pandemic preparedness experts, including from the Department of Global Health, School of Medicine and School of Public Health.

Negotiating startup life through a crisis

CoMotion’s Ken Meyer moderated a discussion with entrepreneur Xiao Wang and investor Dan Rosen on leading a startup through the COVID-19 crisis as part of CoMotion’s Fundamentals for Startups series.

Law in the time of COVID-19

This series examines legal issues at play in managing or reacting to the global public health crisis. The course features public panels on various political, constitutional and legal principles involved in short- and long-term crisis response efforts, with an ultimate focus on students’ opportunities to learn about and help Seattle’s most vulnerable communities.

Surviving the coronavirus infodemic

COVID-19 is more than just a physical illness — inaccurate and incomplete information spreads just as rapidly around the globe, complicating efforts to contain the virus and keep communities safe and healthy. Experts from the University of Washington and Washington State University addressed coronavirus misinformation. Panelists shared tools and tips for concerned citizens to cut through the confusion and build healthier information practices.

COVID-19 vaccines

Be boundless

Connect with us:.

© 2024 University of Washington | Seattle, WA

• Weill Cornell Medicine

Medicine Grand Rounds: COVID-19 presentations

A video of this lecture is available online to members of the Weill Cornell community. You will need to provide your CWID and password. Below are the PowerPoints that were included in the presentation.

Coronavirus Disease 2019 (COVID-19) Clinical Presentation

• Author: David J Cennimo, MD, FAAP, FACP, FIDSA, AAHIVS; Chief Editor: Michael Stuart Bronze, MD  more...
• Sections Coronavirus Disease 2019 (COVID-19)
• Practice Essentials
• Route of Transmission
• Pathophysiology
• Epidemiology
• Physical Examination
• Complications
• Approach Considerations
• Laboratory Studies
• CT Scanning
• Chest Radiography
• Medical Care
• Antiviral Agents
• Immunomodulators and Other Investigational Therapies
• Investigational Antibody-Directed Therapies
• Antithrombotics
• Renin Angiotensin System Blockade and COVID-19
• Diabetes and COVID-19
• Therapies Determined Ineffective
• QT Prolongation with Potential COVID-19 Pharmacotherapies
• Investigational Devices
• Guidelines Summary
• Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing by the Infectious Diseases Society of America
• Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023) by the Infectious Diseases Society of America (IDSA)
• Infectious Diseases Society of America (IDSA) Management Guidelines
• CDC Sample Collection and Testing Guidelines for COVID-19
• Thromboembolism Prevention and Treatment
• Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2 by the CDC
• Guidance for Hospitals on Containing Spread of COVID-19
• CDC Evaluating and Testing Persons Under Investigation (PUI) for COVID-19 Clinical Guidelines
• Medication Summary
• Corticosteroids
• Immunomodulators
• Complement Inhibitors
• COVID-19, Monoclonal Antibodies
• Questions & Answers
• Media Gallery

COVID-19 can manifest with a range of symptoms from mild to severe, such as fever, cough, shortness of breath, malaise, and respiratory distress, [ 46 , 102 ]    typically appearing 2 days to 2 weeks after exposure. Xu et al's analysis of Omicron subvariants revealed no significant differences in key time-to-event periods, with Omicron BA.1 showing the shortest incubation period at 3.49 days. Variability in estimates across virus lineages suggests differences in study populations and interventions. [ 103 ]

Another study found a mean incubation period of 5.1 days, with the majority developing symptoms within 11.5 days. [ 104 ]    Both treated and untreated patients experienced symptom and viral rebound effects, indicating potential challenges in managing the disease [ 105 ]  These studies provide valuable insights into time-to-event periods and transmission dynamics across different COVID-19 variants, contributing to our understanding of the evolving pandemic.

The following symptoms may indicate COVID-19 [ 102 ] :

• Fever or chills
• Shortness of breath or difficulty breathing
• Muscle or body aches
• New loss of taste or smell
• Sore throat
• Congestion or runny nose
• Nausea or vomiting

Other reported symptoms include the following:

• Sputum production
• Respiratory distress
• Neurologic (eg, headache, altered mentality) 

An extensive analysis by Wu and McGoogan revealed that 81% of COVID-19 cases were mild, 14% severe, 5% critical, and 2.3% fatal, with consistent findings observed across multiple studies [ 106 , 107 , 108 ] ; Williamson et al further emphasized that severe disease and mortality were more common in males, older individuals, those in poverty, Black individuals, and patients with specific medical conditions. [ 109 ]

Additional research highlighted the predictive value of frailty over age or comorbidities, [ 110 ] the potential risk associated with blood type A, the protective effect of blood type O, [ 111 , 112 ] and common symptoms like anosmia and ageusia, underscoring the need for prompt reporting and appropriate precautions for suspected cases. [ 6 , 113 , 114 , 115 , 9 ]

Patients who are under investigation for COVID-19 should be evaluated in a private room with the door closed (an airborne infection isolation room is ideal) and asked to wear a surgical mask. All other standard contact and airborne precautions should be observed, and treating healthcare personnel should wear eye protection. [ 9 ]

The most common serious manifestation of COVID-19 upon initial presentation is pneumonia. Fever, cough, dyspnea, and abnormalities on chest imaging are common in these cases. [ 116 , 117 , 118 , 119 ]

Huang and colleagues found that, among patients with pneumonia, 99% had fever, 70% reported fatigue, 59% had dry cough, 40% had anorexia, 35% experienced myalgias, 31% had dyspnea, and 27% had sputum production. [ 116 ]

Complications of COVID-19 include  pneumonia ,  acute respiratory distress syndrome , cardiac injury, arrhythmia,  septic shock , liver dysfunction,  acute kidney injury , and multi-organ failure, among others.

Approximately 5% of patients with COVID-19, and 20% of those hospitalized, experience severe symptoms necessitating intensive care. The common complications among hospitalized patients include pneumonia (75%), ARDS (15%), AKI (9%), and acute liver injury (19%). Cardiac injury has been increasingly noted, including troponin elevation, acute heart failure, dysrhythmias, and myocarditis. Ten percent to 25 percent of hospitalized patients with COVID-19 experience prothrombotic coagulopathy resulting in venous and arterial thromboembolic events. Neurologic manifestations include impaired consciousness and stroke. ICU case fatality is reported up to 40%. [ 107 ]  

Patients with long-term post-COVID-19 symptoms may experience fatigue, dyspnea, cough, anxiety, depression, "brain fog," gastrointestinal issues, sleep difficulties, joint pain, and chest pain for weeks to months after acute illness, a condition referred to as Post-acute sequelae of SARS-CoV-2 (PASC) or long COVID. Guidelines from the NIH and UK NICE define long COVID as persistent symptoms lasting over 12 weeks after COVID-19 infection, with ongoing research aimed at understanding these lingering symptoms. [ 120 ] [ 121 ]

Luo et al conducted a systematic review and meta-analysis or 211 studies involving more than 13 million individuals to assess persistent symptoms after COVID-19. [ 122 ] Common symptoms included fatigue, dyspnea, post-traumatic stress disorder, anxiety, and depression. Factors associated with a higher prevalence of persistent symptoms included female gender, older age, severe illness during acute COVID-19, multiple comorbidities, prolonged hospital stay, and high body mass index. Patients with severe illness in the acute phase or from Europe tended to exhibit a higher prevalence of certain symptoms, whereas children had lower rates. Individuals with COVID-19 had a significantly higher prevalence of persistent symptoms compared to non-COVID-19 individuals. The researchers report that their findings emphasize the need for long-term monitoring and support for COVID-19 survivors.

Please see  Long COVID-19 .

Reinfection

COVID-19 reinfection is defined as an infected person who has undergone full vaccination, whether they have had a booster or boosters. According to the CDC, reinfection is COVID-19 infection of an individual with 2 different viral strains that occurs at least 45 days apart. It also may occur when an individual has 2 positive CoV-2 RT-PCR tests with negative tests between the 2 positive tests. [ 123 , 124 ]

Anecdotal reports have suggested the return of COVID-19 symptoms shortly after completing a 5-day antiviral course in both high and lower risk patients. A retrospective cohort study during the Omicron variant phase from January through June 2022 found COVID-19 rebound rates after nirmatrelvir/ritonavir and molnupiravir treatment. These rates included percentages for COVID-19 infection, symptoms, and hospitalizations at 7-day and 30-day intervals. [ 125 ] The CDC has also issued a health advisory regarding rebound cases in May 2022.

Pfizer, the manufacturer of nirmatrelvir/ritonavir, announced that the drug did not show a statistically significant effect in preventing active disease in those exposed to active cases, with no genomic evidence of resistance. [ 126 ] Concerns have been raised about treatment failures, risk factors, immune response interference, and the contagiousness of relapsed patients. [ 127 , 128 ]

There is a belief that all individuals with confirmed COVID-19 should be started on nirmatrelvir/ritonavir, regardless of their clinical state. The optimal duration of therapy and patient factors contributing to rebound infections require further exploration. Current therapeutic approaches are based on limited data, and individualized regimens guided by symptoms, physical findings, and laboratory results are recommended.

Nirmatrelvir/ritonavir is considered a bridging antiviral and may need to be reevaluated as variants of concern can develop resistance quickly. Other antivirals may be more effective as the virus evolves.

CDC. About COVID-19. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/covid/about/index.html . June 13, 2024; Accessed: August 26, 2024.

Tanaka H, Ogata T, Shibata T, Nagai H, Takahashi Y, Kinoshita M, et al. Shorter Incubation Period among COVID-19 Cases with the BA.1 Omicron Variant. Int J Environ Res Public Health . 2022 May 23. 19 (10): [QxMD MEDLINE Link] .

Clinical characteristics of COVID-19. European Centre for Disease Prevention and Control. Available at https://www.ecdc.europa.eu/en/covid-19/latest-evidence/clinical . Updated: 30 May 2023; Accessed: August 28, 2024.

Hentsch L, Cocetta S, Allali G, Santana I, Eason R, Adam E, et al. Breathlessness and COVID-19: A Call for Research. Respiration . 2021. 100 (10):1016-1026. [QxMD MEDLINE Link] .

Zoghi G, Moosavy SH, Yavarian S, HasaniAzad M, Khorrami F, Sharegi Brojeni M, et al. Gastrointestinal implications in COVID-19. BMC Infect Dis . 2021 Nov 4. 21 (1):1135. [QxMD MEDLINE Link] .

Rabin RC. Lost Sense of Smell May Be Peculiar Clue to Coronavirus Infection. The New York Times. Available at https://www.nytimes.com/2020/03/22/health/coronavirus-symptoms-smell-taste.html . March 22, 2020; Accessed: August 28, 2024.

Coelho DH, Reiter ER, French E, Costanzo RM. Decreasing Incidence of Chemosensory Changes by COVID-19 Variant. Otolaryngol Head Neck Surg . 2022 May 3. 1945998221097656. [QxMD MEDLINE Link] .

CDC. Respiratory Virus Guidance. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/respiratory-viruses/guidance/index.html . March 1, 2024; Accessed: August 26, 2024.

CDC. Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html . March 18, 2024; Accessed: August 24, 2024.

Rizk JG, Forthal DN, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, et al. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. Drug Discov Today . 2020 Nov 27. [QxMD MEDLINE Link] . [Full Text] .

Gallegos A. WHO Declares Public Health Emergency for Novel Coronavirus. Medscape Medical News. Available at https://www.medscape.com/viewarticle/924596 . January 30, 2020; Accessed: August 28, 2024.

Ramzy A, McNeil DG. W.H.O. Declares Global Emergency as Wuhan Coronavirus Spreads. The New York Times. Available at https://nyti.ms/2RER70M . January 30, 2020; Accessed: August 28, 2024.

The New York Times. Coronavirus Live Updates: W.H.O. Declares Pandemic as Number of Infected Countries Grows. The New York Times. Available at https://www.nytimes.com/2020/03/11/world/coronavirus-news.html#link-682e5b06 . March 11, 2020; Accessed: August 28, 2024.

Coronavirus Updates: The Illness Now Has a Name: COVID-19. The New York Times. Available at https://www.nytimes.com/2020/02/11/world/asia/coronavirus-china.html . February 11, 2020; Accessed: August 28, 2024.

WHO. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. World Health Organization. Available at https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 . February 11, 2020; Accessed: August 28, 2024.

Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus – The species and its viruses, a statement of the Coronavirus Study Group. Available at https://read.qxmd.com/doi/10.1101/2020.02.07.937862 . February 11, 2020; Accessed: August 28, 2024.

US Department of Health and Human Services. Fact Sheet: End of the COVID-19 Public Health Emergency. May 9, 2023. Available at https://www.hhs.gov/about/news/2023/05/09/fact-sheet-end-of-the-covid-19-public-health-emergency.html .

CDC. Masks and Respiratory Viruses Prevention. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/respiratory-viruses/prevention/masks.html . March 1, 2024; Accessed: August 29, 2024.

Honein MA, Christie A, Rose DA, et al. Summary of guidance for public health strategies to address high levels of community transmission of SARS-CoV-2 and related deaths, December 2020. MMWR Morb Mortal Wkly Rep . 2020 Dec 04. [Full Text] .

Centers for Disease Control and Prevention. How to Protect Yourself & Others. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/covid/prevention/?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html . July 12, 2024; Accessed: August 28, 2024.

Abutaleb Y. How the new coronavirus differs from SARS, measles and Ebola. The Washington Post. Available at https://www.washingtonpost.com/health/how-the-new-coronavirus-differs-from-sars-measles-and-ebola/2020/01/23/aac6bb06-3e1b-11ea-b90d-5652806c3b3a_story.html . January 23, 2020; Accessed: August 28, 2024.

World Health Organization. MERS situation update, May 2024. WHO Regional Office for the Eastern Mediterranean. Available at https://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html . May 2024; Accessed: August 27, 2024.

WHO. Leading health agencies outline updated terminology for pathogens that transmit through the air. News Release. World Health Organization. Available at https://www.who.int/news/item/18-04-2024-leading-health-agencies-outline-updated-terminology-for-pathogens-that-transmit-through-the-air . April 18, 2024; Accessed: August 28, 2024.

Handiso TB, Jifar MS, Nuriye Hagisso S. Coronavirus's (SARS-CoV-2) airborne transmission. SAGE Open Med . 2022. 10:20503121221094185. [QxMD MEDLINE Link] .

Centers for Disease Control and Prevention. Standard Operating Procedure (SOP) for Triage of Suspected COVID-19 Patients. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/covid/hcp/non-us-settings/sop-triage-prevent-transmission.html . Updated August 1, 2024; Accessed: August 28, 2024.

Morawska L, Milton DK. It is Time to Address Airborne Transmission of COVID-19. Clin Infect Dis . 2020 Jul 6. [QxMD MEDLINE Link] .

Mask use in the context of COVID-19 (1 December 2020). World Health Organization. Available at https://www.who.int/publications/i/item/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak . December 1, 2020; Accessed: August 28, 2024.

Tandjaoui-Lambiotte Y, Elabbadi A, Marouane B, Besset S, Roux D, Ebstein N, et al. Routes of SARS-Cov2 transmission in the intensive care unit: A multicentric prospective study. J Infect Public Health . 2024 Aug. 17 (8):102454. [QxMD MEDLINE Link] . [Full Text] .

van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med . 2020 Mar 17. [QxMD MEDLINE Link] .

Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different environmental conditions. The Lancet Microbe . April 2, 2020. [Full Text] .

Rahmani A, Dini G, Leso V, Montecucco A, Kusznir Vitturi B, Iavicoli I, et al. Duration of SARS-CoV-2 shedding and infectivity in the working age population: a systematic review and meta-analysis. Med Lav . 2022 Apr 26. 113 (2):e2022014. [QxMD MEDLINE Link] .

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet . 2020 Mar 11. [QxMD MEDLINE Link] .

Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis . 2020 Mar 19. [QxMD MEDLINE Link] .

Zhou B, She J, Wang Y, Ma X. The duration of viral shedding of discharged patients with severe COVID-19. Clin Infect Dis . 2020 Apr 17. [QxMD MEDLINE Link] .

Mole B. Recovered COVID-19 patients test positive but not infectious, data finds. Ars Technica. Available at https://arstechnica.com/science/2020/05/feared-reactivation-of-covid-19-infections-disputed-by-new-data/ . May 19, 2020; Accessed: August 28, 2024.

Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med . 2020 Dec 24. 383 (26):2586-2588. [QxMD MEDLINE Link] . [Full Text] .

Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman M, et al. Prolonged SARS-CoV-2 replication in an immunocompromised patient. J Infect Dis . 2020 Oct 22. [QxMD MEDLINE Link] . [Full Text] .

Li D, Jin M, Bao P, Zhao W, Zhang S. Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019. JAMA Netw Open . 2020 May 1. 3 (5):e208292. [QxMD MEDLINE Link] .

Oordt-Speets AM, Spinardi JR, Mendoza CF, Yang J, Del Carmen Morales G, Kyaw MH. Duration of SARS-CoV-2 shedding: A systematic review. J Glob Health . 2024 Mar 29. 14:05005. [QxMD MEDLINE Link] . [Full Text] .

Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann Intern Med . 2020 Sep 1. 173 (5):362-367. [QxMD MEDLINE Link] . [Full Text] .

Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Netw Open . 2021 Jan 4. 4 (1):e2035057. [QxMD MEDLINE Link] . [Full Text] .

Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med . 2020 Feb 19. [QxMD MEDLINE Link] .

Mukherjee R, Satardekar R. Why are some coronavirus variants more infectious?. J Biosci . 2021. 46 (4): [QxMD MEDLINE Link] . [Full Text] .

Ivanova N, Sotirova Y, Gavrailov G, Nikolova K, Andonova V. Advances in the Prophylaxis of Respiratory Infections by the Nasal and the Oromucosal Route: Relevance to the Fight with the SARS-CoV-2 Pandemic. Pharmaceutics . 2022 Feb 27. 14 (3): [QxMD MEDLINE Link] . [Full Text] .

Lasbleiz A, Gaborit B, Soghomonian A, Bartoli A, Ancel P, Jacquier A, et al. COVID-19 and Obesity: Role of Ectopic Visceral and Epicardial Adipose Tissues in Myocardial Injury. Front Endocrinol (Lausanne) . 2021. 12:726967. [QxMD MEDLINE Link] . [Full Text] .

Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis . 2020 Jan 14. 91:264-266. [QxMD MEDLINE Link] .

Garcia-Vidal C, Moreno-García E, Hernández-Meneses M, Puerta-Alcalde P, Chumbita M, Garcia-Pouton N, et al. Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019. Clin Infect Dis . 2022 Jan 7. 74 (1):127-132. [QxMD MEDLINE Link] . [Full Text] .

Fang L, Karakiulakis G, Roth M. Correction to Lancet Respir Med 2020; 8: e21. Lancet Respir Med . 2020 Jun. 8 (6):e54. [QxMD MEDLINE Link] . [Full Text] .

CDC COVID-19 Response Team, Jorden MA, Rudman SL, et al. Evidence for Limited Early Spread of COVID-19 Within the United States, January-February 2020. MMWR. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments . May 29, 2020; Accessed: August 28, 2024.

WHO. WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization. Available at https://data.who.int/dashboards/covid19 . August 11, 2024; Accessed: August 26, 2024.

Ahmad FB, Cisewski JA, Miniño A, Anderson RN. Provisional Mortality Data - United States, 2020. MMWR Morb Mortal Wkly Rep . 2021 Apr 9. 70 (14):519-522. [QxMD MEDLINE Link] . [Full Text] .

Ahmad FB, Cisewski JA, Anderson RN. Provisional Mortality Data - United States, 2021. MMWR Morb Mortal Wkly Rep . 2022 Apr 29. 71 (17):597-600. [QxMD MEDLINE Link] . [Full Text] .

Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. N Engl J Med . 2020 Jun 25. 382 (26):2534-2543. [QxMD MEDLINE Link] . [Full Text] .

Ricardo AC, Chen J, Toth-Manikowski SM, Meza N, Joo M, Gupta S, et al. Hispanic ethnicity and mortality among critically ill patients with COVID-19. PLoS One . 2022. 17 (5):e0268022. [QxMD MEDLINE Link] . [Full Text] .

Khanijahani A, Iezadi S, Gholipour K, Azami-Aghdash S, Naghibi D. A systematic review of racial/ethnic and socioeconomic disparities in COVID-19. Int J Equity Health . 2021 Nov 24. 20 (1):248. [QxMD MEDLINE Link] .

Zelner J, Trangucci R, Naraharisetti R, Cao A, Malosh R, Broen K, et al. Racial disparities in COVID-19 mortality are driven by unequal infection risks. Clin Infect Dis . 2020 Nov 21. [QxMD MEDLINE Link] . [Full Text] .

Tai DBG, Shah A, Doubeni CA, Sia IG, Wieland ML. The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States. Clin Infect Dis . 2020 Jun 20. [QxMD MEDLINE Link] . [Full Text] .

Millet C, Racoosin E, Narvar S, Horani G, et al. The Racial Divide: A Follow Up Study on Racial Disparity Amongst COVID-19 Survivors in an Urban Community. J Community Hosp Intern Med Perspect . 2022 May 2. 12(3):66-70. [QxMD MEDLINE Link] . [Full Text] .

Hobbs CV, Kim SS, Vemula P, Inagaki K, et al. Active Surveillance With Seroprevalence-based Infection Rates Indicates Racial Disparities With Pediatric SARS-CoV-2 Requiring Hospitalization in Mississippi, March 2020-February 2021. Pediatr Infect Dis J . 2022 Jun 7. [QxMD MEDLINE Link] .

Ward LA, Black KP, Britton CL, Tompkins ML, Provost EM. COVID-19 Cases, Hospitalizations, and Deaths Among American Indian or Alaska Native Persons - Alaska, 2020-2021. MMWR Morb Mortal Wkly Rep . 2022 Jun 3. 71 (22):730-733. [QxMD MEDLINE Link] .

Malik S, Opara I, Lardier DT Jr, Younger J, Greene RN. Young Adults at the National Epicenter of the COVID-19 Outbreak: Understanding the Impact and Future Challenges of Social Distancing on Mental Health Outcomes. Int J Environ Res Public Health . 2023 Dec 26. 21 (1): [QxMD MEDLINE Link] . [Full Text] .

Cunningham JW, Vaduganathan M, Claggett BL, Jering KS, Bhatt AS, Rosenthal N, et al. Clinical Outcomes in Young US Adults Hospitalized With COVID-19. JAMA Intern Med . 2020 Sep 9. [QxMD MEDLINE Link] . [Full Text] .

Park YJ, Choe YJ, Park O, and the, COVID-19 National Emergency Response Center, Epidemiology and Case Management Team. Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020. Emerg Infect Dis . 2020 Oct. 26 (10):2465-2468. [QxMD MEDLINE Link] . [Full Text] .

Schwartz NG, Moorman AC, Makaretz A, Chang KT, Chu VT, Szablewski CM, et al. Adolescent with COVID-19 as the Source of an Outbreak at a 3-Week Family Gathering - Four States, June-July 2020. MMWR Morb Mortal Wkly Rep . 2020 Oct 9. 69 (40):1457-1459. [QxMD MEDLINE Link] . [Full Text] .

Children and COVID-19: State-Level Data Report. American Academy of Pediatrics. Available at https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/ . 2022 Oct 27; Accessed: November 7, 2022.

Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis . 2020 Nov. 20 (11):e276-e288. [QxMD MEDLINE Link] .

Feldstein LR, Tenforde MW, Friedman KG, and the, Overcoming COVID-19 Investigators. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA . 2021 Feb 24. [QxMD MEDLINE Link] . [Full Text] .

Ko JY, DeSisto CL, Simeone RM, Ellington S, Galang RR, Oduyebo T, et al. Adverse Pregnancy Outcomes, Maternal Complications, and Severe Illness Among US Delivery Hospitalizations With and Without a Coronavirus Disease 2019 (COVID-19) Diagnosis. Clin Infect Dis . 2021 Jul 15. 73 (Suppl 1):S24-S31. [QxMD MEDLINE Link] . [Full Text] .

Wang H, Li N, Sun C, Guo X, Su W, Song Q, et al. The association between pregnancy and COVID-19: A systematic review and meta-analysis. Am J Emerg Med . 2022 Apr 6. 56:188-195. [QxMD MEDLINE Link] .

Ayala-Ramírez P, González M, Escudero C, Quintero-Arciniegas L, Giachini FR, Alves de Freitas R, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Pregnancy. A Non-systematic Review of Clinical Presentation, Potential Effects of Physiological Adaptations in Pregnancy, and Placental Vascular Alterations. Front Physiol . 2022. 13:785274. [QxMD MEDLINE Link] .

DeSisto CL, Wallace B, Simeone RM, Polen K, Ko JY, Meaney-Delman D, et al. Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization - United States, March 2020-September 2021. MMWR Morb Mortal Wkly Rep . 2021 Nov 26. 70 (47):1640-1645. [QxMD MEDLINE Link] . [Full Text] .

Marín Gabriel MA, Reyne Vergeli M, Caserío Carbonero S, Sole L, Carrizosa Molina T, Rivero Calle I, et al. Maternal, Perinatal and Neonatal Outcomes With COVID-19: A Multicenter Study of 242 Pregnancies and Their 248 Infant Newborns During Their First Month of Life. Pediatr Infect Dis J . 2020 Sep 11. [QxMD MEDLINE Link] .

Adhikari EH, Moreno W, Zofkie AC, MacDonald L, McIntire DD, Collins RRJ, et al. Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection. JAMA Netw Open . 2020 Nov 2. 3 (11):e2029256. [QxMD MEDLINE Link] .

Chambers C, Krogstad P, Bertrand K, Contreras D, Tobin NH, Bode L, et al. Evaluation for SARS-CoV-2 in Breast Milk From 18 Infected Women. JAMA . 2020 Aug 19. [QxMD MEDLINE Link] . [Full Text] .

Pace RM, Williams JE, Järvinen KM, Meehan CL, Martin MA, Ley SH, et al. Milk From Women Diagnosed With COVID-19 Does Not Contain SARS-CoV-2 RNA but Has Persistent Levels of SARS-CoV-2-Specific IgA Antibodies. Front Immunol . 2021. 12:801797. [QxMD MEDLINE Link] . [Full Text] .

Alam A, Soeroto AA, Susilohadi RA, Chandra LA. Severity of COVID-19 manifestations in HIV patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci . 2024 Mar. 28 (6):2569-2583. [QxMD MEDLINE Link] . [Full Text] .

Dandachi D, Geiger G, Montgomery MW, and the, HIV-COVID-19 consortium. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients with HIV and Coronavirus Disease-19. Clin Infect Dis . 2020 Sep 9. [QxMD MEDLINE Link] . [Full Text] .

Okoh AK, Bishburg E, Grinberg S, Nagarakanti S. COVID-19 Pneumonia in Patients With HIV: A Case Series. J Acquir Immune Defic Syndr . 2020 Sep 1. 85 (1):e4-e5. [QxMD MEDLINE Link] . [Full Text] .

Karmen-Tuohy S, Carlucci PM, Zervou FN, Zacharioudakis IM, Rebick G, Klein E, et al. Outcomes Among HIV-Positive Patients Hospitalized With COVID-19. J Acquir Immune Defic Syndr . 2020 Sep 1. 85 (1):6-10. [QxMD MEDLINE Link] . [Full Text] .

Ho HE, Peluso MJ, Margus C, Matias Lopes JP, He C, Gaisa MM, et al. Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV. J Infect Dis . 2020 Jun 30. [QxMD MEDLINE Link] . [Full Text] .

Oyelade T, Alqahtani JS, Hjazi AM, Li A, Kamila A, Raya RP. Global and Regional Prevalence and Outcomes of COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis. Trop Med Infect Dis . 2022 Feb 3. 7 (2): [QxMD MEDLINE Link] .

Self WH, Tenforde MW, Stubblefield WB, and the, CDC COVID-19 Response Team IVY Network. Seroprevalence of SARS-CoV-2 among frontline health care personnel in a multistate hospital network – 13 academic medical centers, April-June 2020. MMWR Morb Mortal Wkly Rep . 2020 Aug 31. 69: [Full Text] .

Li C, Islam N, Gutierrez JP, Gutiérrez-Barreto SE, Castañeda Prado A, Moolenaar RL, et al. Associations of diabetes, hypertension and obesity with COVID-19 mortality: a systematic review and meta-analysis. BMJ Glob Health . 2023 Dec 14. 8 (12): [QxMD MEDLINE Link] . [Full Text] .

Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol . 2020 Aug 13. [QxMD MEDLINE Link] . [Full Text] .

Bhatt AS, Kosiborod MN, Claggett BL, et al. Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. Eur J Heart Fail . 2023 Dec. 25 (12):2177-2188. [QxMD MEDLINE Link] . [Full Text] .

O'Hearn M, Liu J, Cudhea F, Micha R, Mozaffarian D. Coronavirus Disease 2019 Hospitalizations Attributable to Cardiometabolic Conditions in the United States: A Comparative Risk Assessment Analysis. J Am Heart Assoc . 2021 Feb. 10 (5):e019259. [QxMD MEDLINE Link] . [Full Text] .

IDSA. COVID-19 Variant Update. Infectious Diseases Society of America. Available at https://www.idsociety.org/covid-19-real-time-learning-network/diagnostics/covid-19-variant-update/#/+/0/publishedDate_na_dt/desc/ . August 28, 2024; Accessed: August 30, 2024.

Hu FH, Jia YJ, Zhao DY, Fu XL, Zhang WQ, Tang W, et al. Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients. Clin Microbiol Infect . 2023 Jul. 29 (7):835-844. [QxMD MEDLINE Link] . [Full Text] .

Ahmad SJ, Degiannis JR, Borucki J, Pouwels S, Rawaf DL, Lala A, et al. Fatality Rates After Infection With the Omicron Variant (B.1.1.529): How Deadly has it been? A Systematic Review and Meta-Analysis. J Acute Med . 2024 Jun 1. 14 (2):51-60. [QxMD MEDLINE Link] . [Full Text] .

Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Viruses . 2023 Jan 5. 15 (1): [QxMD MEDLINE Link] . [Full Text] .

Garg N, Kunamneni AS, Garg P, Sharma S, Sharma D, Kunamneni A. Antiviral Drugs and Vaccines for Omicron Variant: A Focused Review. Can J Infect Dis Med Microbiol . 2023. 2023:6695533. [QxMD MEDLINE Link] . [Full Text] .

Vangeel L, De Jonghe S, Maes P, Slechten B, Raymenants J, André E, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern. bioRxiv . 2021 Dec 28. [Full Text] .

Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv . 2021 Dec 02. [Full Text] .

Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. medRxiv . 2021 Dec 13. [Full Text] .

Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv . 2021 May 03. [Full Text] .

Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv . 2021 May 10. [Full Text] .

Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med . 2021 Jul 21. [QxMD MEDLINE Link] . [Full Text] .

Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Report 42 - Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. Imperial College London, MRC Centre for Global Infectious Disease Analysis. Available at https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-12-31-COVID19-Report-42-Preprint-VOC.pdf . 2020 Dec 31; Accessed: August 28, 2024.

Nelson G, Oleksandr B, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P. Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N401Y mutations (501Y.V2 variant) induces conformational change greater than N401Y mutant alone, potentially resulting in an escape mutant. bioRxiv . 2021 Jan 13. [Full Text] .

Sabino EC, Buss LF, Carvalho MPS, Prete CA, Crispim MAE, Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet . 2021 Jan 27. [Full Text] .

CDC. Symptoms of Coronavirus. CDC. Available at https://www.cdc.gov/covid/signs-symptoms/?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html . Updated July 25, 2024; Accessed: August 28, 2024.

Xu X, Wu Y, Kummer AG, Zhao Y, Hu Z, Wang Y, et al. Assessing changes in incubation period, serial interval, and generation time of SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med . 2023 Sep 29. 21 (1):374. [QxMD MEDLINE Link] . [Full Text] .

Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med . 2020 Mar 10. [QxMD MEDLINE Link] .

Deo R, Choudhary MC, Moser C, and the, ACTIV-2/A5401 Study Team†. Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection. Ann Intern Med . 2023 Feb 21. [QxMD MEDLINE Link] . [Full Text] .

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA . 2020 Feb 24. [QxMD MEDLINE Link] .

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA . 2020 Aug 25. 324 (8):782-793. [QxMD MEDLINE Link] .

Burke RM, Killerby ME, Newton S, Ashworth CE, Berns AL, Brennan S, et al. Symptom Profiles of a Convenience Sample of Patients with COVID-19 - United States, January-April 2020. MMWR Morb Mortal Wkly Rep . 2020 Jul 17. 69 (28):904-908. [QxMD MEDLINE Link] .

Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature . 2020 Jul 8. [QxMD MEDLINE Link] .

Hewitt J, Carter B, Vilches-Moraga A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health . 2020 Jun 30. [QxMD MEDLINE Link] .

Ellinghaus D, Degenhardt F, Bujanda L, et al. The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis. medRxiv. Available at https://www.medrxiv.org/content/10.1101/2020.05.31.20114991v1 . June 2, 2020; Accessed: August 28, 2024.

Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 With Respiratory Failure. NEJM . 2020 Jun 17. [QxMD MEDLINE Link] . [Full Text] .

CDC. Healthcare Professionals: Information on COVID-19. CDC. Available at https://www.cdc.gov/covid/hcp/?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html . March 31, 2021 (updated); Accessed: August 28, 2024.

Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA . 2020 Apr 22. [QxMD MEDLINE Link] .

Luers JC, Rokohl AC, Loreck N, Wawer Matos PA, Augustin M, Dewald F, et al. Olfactory and Gustatory Dysfunction in Coronavirus Disease 19 (COVID-19). Clin Infect Dis . 2020 May 1. [QxMD MEDLINE Link] .

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet . 2020 Jan 24. [QxMD MEDLINE Link] .

Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med . 2020 Feb 28. [QxMD MEDLINE Link] .

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet . 2020 Feb 15. 395 (10223):507-513. [QxMD MEDLINE Link] .

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA . 2020 Feb 7. [QxMD MEDLINE Link] .

CDC. Clinical Overview of Long COVID. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html . July 12, 2024; Accessed: August 28, 2024.

[Guideline] NICE. COVID-19 rapid guideline: managing the long-term effects of COVID-19. National Institute for Health and Care Excellence (NICE). Available at https://www.nice.org.uk/guidance/NG188 . 2020 Dec 18; Accessed: August 27, 2024.

Luo D, Mei B, Wang P, Li X, Chen X, Wei G, et al. Prevalence and risk factors for persistent symptoms after COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect . 2024 Mar. 30 (3):328-335. [QxMD MEDLINE Link] . [Full Text] .

Sciscent BY, Eisele CD, Ho L, King SD, Jain R, Golamari RR. COVID-19 reinfection: the role of natural immunity, vaccines, and variants. J Community Hosp Intern Med Perspect . 2021. 11 (6):733-739. [QxMD MEDLINE Link] .

Ren X, Zhou J, Guo J, Hao C, Zheng M, Zhang R, et al. Reinfection in patients with COVID-19: a systematic review. Glob Health Res Policy . 2022 Apr 29. 7 (1):12. [QxMD MEDLINE Link] . [Full Text] .

Hammond J, Leister-Tebbe H, Gardner A, and the, EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med . 2022 Feb 16. [QxMD MEDLINE Link] . [Full Text] .

Lazar K. A puzzling phenomenon: Patients report a rebound of COVID. A puzzling phenomenon: Patients report a rebound of COVID-19 symptoms after taking antiviral Paxlovid. April 21, 2022. Available at https://www.bostonglobe.com/2022/04/21/metro/puzzling-phenomenon-patients-report-rebound-covid-19-symptoms-after-taking-antiviral-paxlovid/ .

Rubin EJ, Longo DL, Baden LR. Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup. N Engl J Med . 2021 Apr 22. 384 (16):1564-1565. [QxMD MEDLINE Link] . [Full Text] .

Yes, Relapses After Paxlovid Happen — Now What?. NEJM Journal Watch. Available at https://blogs.jwatch.org/hiv-id-observations/index.php/yes-relapses-after-paxlovid-happen-now-what/2022/04/25/ . April 25, 2022; Accessed: August 29, 2024.

CDC. COVID-19 Frequently Asked Questions. CDC. Available at https://www.cdc.gov/nchs/covid19/faq.htm . Reviewed August 24, 2024; Accessed: August 28, 2024.

FDA. Coronavirus (COVID-19) Update: Daily Roundup. fda.gov. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup . March 23, 2020; Accessed: August 28, 2024.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med . 2020 Mar 13. [QxMD MEDLINE Link] .

Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis . 2020 Feb 24. [QxMD MEDLINE Link] .

Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. AJR Am J Roentgenol . 2020 Mar 3. 1-6. [QxMD MEDLINE Link] .

Alilou S, Zangiabadian M, Pouramini A, Jaberinezhad M, Shobeiri P, Ghozy S, et al. Radiological Findings as Predictors of COVID-19 Lung Sequelae: A Systematic Review and Meta-analysis. Acad Radiol . 2023 Dec. 30 (12):3076-3085. [QxMD MEDLINE Link] . [Full Text] .

Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology . 2020 Mar 10. 200823. [QxMD MEDLINE Link] .

ACR. ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection. American College of Radiology. Available at https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection . March 22, 2020; Accessed: August 28, 2024.

Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci . 2020 Mar 4. [QxMD MEDLINE Link] .

Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis . 2020 Mar 17. [QxMD MEDLINE Link] .

Li M, Lei P, Zeng B, Li Z, Yu P, Fan B, et al. Coronavirus Disease (COVID-19): Spectrum of CT Findings and Temporal Progression of the Disease. Acad Radiol . 2020 Mar 20. [QxMD MEDLINE Link] .

Wong HYF, Lam HYS, Fong AH, Leung ST, Chin TW, Lo CSY, et al. Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients. Radiology . 2019 Mar 27. 201160. [QxMD MEDLINE Link] .

Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of Unknown Etiology in Wuhan, China: Potential for International Spread Via Commercial Air Travel. J Travel Med . 2020 Jan 14. [QxMD MEDLINE Link] .

Veklury (remdesivir) [package insert]. Foster City, CA: Gilead Sciences, Inc. February 2024. Available at [Full Text] .

RECOVERY Collaborative Group., Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med . 2021 Feb 25. 384 (8):693-704. [QxMD MEDLINE Link] . [Full Text] .

WHO. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19. WHO. Available at https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19 . April 19, 2020; Accessed: August 28, 2024.

[Guideline] Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. IDSA. Available at https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ . 2021 Oct 01; updated 6/26/2023; Accessed: August 28, 2024.

Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O’Mera MJ, et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. bioRxiv. Available at https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1 . 2020 Mar 22; Accessed: August 28, 2024.

Arshad U, Pertinez H, Box H, Tatham L, Rajoki RKR, Curley P, et al. Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics. medRxiv . 2020 Apr 22. [Full Text] .

World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. WHO. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments . 2020 Oct 16; Accessed: August 28, 2024.

WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med . 2020 Dec 2. [QxMD MEDLINE Link] . [Full Text] .

Kalil AC. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA . 2020 Mar 24. [QxMD MEDLINE Link] . [Full Text] .

Rome BN, Avorn J. Drug Evaluation during the Covid-19 Pandemic. N Engl J Med . 2020 Apr 14. [QxMD MEDLINE Link] . [Full Text] .

Frellick M. Key Drugs Join PPEs on List of Front-Line Shortages. Medscape Medical News . 2020 Apr 02. Available at https://www.medscape.com/viewarticle/928039 .

Live Updates: Which Drugs Are In Shortage Because of COVID-19?. GoodRx. Available at https://www.goodrx.com/blog/covid-19-drug-shortages-updates/ . July 13, 2020; Accessed: August 28, 2024.

Wilson FP. Hydroxychloroquine for COVID-19: What’s the Evidence? (Commentary). Medscape Medical News and Perspectives . 2020 Mar 25. Available at https://www.medscape.com/viewarticle/927342 .

CDC. Underlying Conditions and the Higher Risk for Severe COVID-19. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html . July 30, 2024; Accessed: August 26, 2024.

NPR. CDC Now Recommends Americans Consider Wearing Cloth Face Coverings In Public. May 3, 2023. Available at https://www.npr.org/sections/coronavirus-live-updates/2020/04/03/826219824/president-trump-says-cdc-now-recommends-americans-wear-cloth-masks-in-public .

Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med . 2020. [Full Text] .

Smith JD, MacDougall CC, Johnstone J, Copes RA, Schwartz B, Garber GE. Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis. CMAJ . 2016 May 17. 188 (8):567-574. [QxMD MEDLINE Link] .

TLR 2/6/9 agonist PUL-042. NCI Drug Dictionary. Available at https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tlr-2-6-9-agonist-pul-042 . Accessed: August 28, 2024.

The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2. ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT04313023 . 2020 Mar 24; Accessed: August 24, 2024.

The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection. ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT04312997?term=PUL-042&cond=COVID&cntry=US&draw=2&rank=2 . 2020 May 07; Accessed: August 28, 2024.

Holshue ML, DeBolt C, Lindquist S, and, the Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med . 2020 Mar 5. 382 (10):929-936. [QxMD MEDLINE Link] .

National Institutes of Health. NIH clinical trial of remdesivir to treat COVID-19 begins. U.S. Department of Health and Human Services. Available at https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins . 2020 Feb 25; Accessed: August 28, 2024.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med . 2020 Oct 8. [QxMD MEDLINE Link] . [Full Text] .

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med . November 5, 2020. 383:1827-1837. [QxMD MEDLINE Link] . [Full Text] .

Spinner CD, Gottlieb RL, Criner GJ, and the, GS-US-540-5774 Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA . 2020 Aug 21. [QxMD MEDLINE Link] . [Full Text] .

Gottlieb RL, Vaca CE, Paredes R, and the, GS-US-540-9012 (PINETREE) Investigators. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med . 2021 Dec 22. [QxMD MEDLINE Link] . [Full Text] .

Veklury (remdesivir) reduced risk of mortality in hospitalized COVID-19 patients across all variant time periods in a real world study of more than 500,000 patients. Gilead . 2023 Jan 21. Available at https://www.gilead.com/news-and-press/press-room/press-releases/2023/2/veklury-remdesivir-reduced-risk-of-mortality-in-hospitalized-covid19-patients-across-all-variant-time-periods-in-a-real-world-study-of-more-than-5 .

Amstutz A, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomized controlled trials. Lancet Respir Med . 2023 Feb 21. [Full Text] .

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19) (CARAVAN). ClinicalTrials.gov. Available at https://www.clinicaltrials.gov/ct2/show/NCT04431453 . 2020 Jun 01; Accessed: August 28, 2024.

Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2. J Pediatric Infect Dis Soc . 2020 Sep 12. [QxMD MEDLINE Link] . [Full Text] .

Burwick RM, Yawetz S, Stephenson KE, Collier AY, Sen P, Blackburn BG, et al. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19. Clin Infect Dis . 2020 Oct 8. [QxMD MEDLINE Link] . [Full Text] .

McCoy JA, Short WR, Srinivas SK, Levine LD, Hirshberg A. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center. Am J Obstet Gynecol MFM . 2020 Aug. 2 (3):100164. [QxMD MEDLINE Link] . [Full Text] .

Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death. Pfizer, Inc . 2021 Dec 14. Available at https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results .

A post-exposure prophylaxis study of PF-07321332/ritonavir in adult household contacts of an individual with symptomatic COVID-19. ClinicalTrials.gov. Available at https://www.clinicaltrials.gov/ct2/show/NCT05047601 . 2021 Dec 01; Accessed: December 14, 2021.

Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and the risk of post-acute sequelae of COVID-19. medRxiv . November 5, 2022. [Full Text] .

Liu J, Pan X, Zhang S, Li M, Ma K, Fan C, et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Reg Health West Pac . 2023 Feb 6. 100694. [QxMD MEDLINE Link] . [Full Text] .

Wong CKH, Lau KTK, Au ICH, Lau EHY, Poon LLM, Hung IFN, et al. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study. Lancet Infect Dis . 2023 Feb 13. [QxMD MEDLINE Link] . [Full Text] .

Zheng Q, Ma P, Wang M, Cheng Y, Zhou M, Ye L, et al. Efficacy and safety of Paxlovid for COVID-19:a meta-analysis. J Infect . 2023 Jan. 86 (1):66-117. [QxMD MEDLINE Link] . [Full Text] .

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, and the, MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med . 2022 Feb 10. 386:509-520. [QxMD MEDLINE Link] . [Full Text] .

Xie Y, Bowe B, Al-Aly Z. Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. BMJ . 2023 Mar 7. 380:e072705. [QxMD MEDLINE Link] . [Full Text] .

Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis. Clin Infect Dis . 2023 Feb 8. 76 (3):453-460. [QxMD MEDLINE Link] . [Full Text] .

Merck provides update on phase 3 MOVe-AHEAD trial evaluating Lagevrio (molnupiravir) for post-exposure prophylaxis for prevention of COVID-19. Merck . 2023 Feb 21. Available at https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/ .

Ingraham NE, Lotfi-Emran S, Thielen BK, Techar K, Morris RS, Holtan SG, et al. Immunomodulation in COVID-19. Lancet Respir Med . 2020 May 4. [QxMD MEDLINE Link] . [Full Text] .

Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs . 2020 Sep. 80 (13):1267-1292. [QxMD MEDLINE Link] . [Full Text] .

Peterson JH, Paranjape NS, Grundlingh N, Priestley JL. Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19. Crit Care Med . 2023 Mar 1. 51 (3):337-346. [QxMD MEDLINE Link] . [Full Text] .

Cawcutt KA, Kalil AC. Baricitinib or Tocilizumab? Treatment of Patients Hospitalized With Severe COVID-19. Crit Care Med . 2023 Mar 1. 51 (3):413-415. [QxMD MEDLINE Link] .

Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis . 2020 Apr. 20 (4):400-402. [QxMD MEDLINE Link] . [Full Text] .

Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet . 2020 Feb 15. 395 (10223):e30-e31. [QxMD MEDLINE Link] . [Full Text] .

Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richarson PJ, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. 2020 Apr 15. [Full Text] .

Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med . 2020 Dec 11. [QxMD MEDLINE Link] . [Full Text] .

Kalil AC, Stebbing J. Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respir Med . 2021 Aug 31. [QxMD MEDLINE Link] . [Full Text] .

Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med . 2021 Aug 31. [QxMD MEDLINE Link] . [Full Text] .

Lilly and Incyte’s baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation. Lilly. Available at https://investor.lilly.com/news-releases/news-release-details/lilly-and-incytes-baricitinib-reduced-deaths-among-patients . 2021 Aug 03; Accessed: August 28, 2024.

Wagner JL, Veve MP, Barber KE. Using IL-6 inhibitors to treat COVID-19. ContagionLive. Available at https://www.contagionlive.com/publications/contagion/2020/august/using-il6-inhibitors-to-treat-covid19?ekey=c2NiZXJnbWFuQG5lYnJhc2thbWVkLmNvbQ . 2020 Aug 17; Accessed: August 28, 2024.

Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med . 2021 Jan 7. 384 (1):20-30. [QxMD MEDLINE Link] . [Full Text] .

Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, Hunter BD, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med . 2021 Nov. 47 (11):1258-1270. [QxMD MEDLINE Link] . [Full Text] .

REMAP-CAP Investigators., Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med . 2021 Apr 22. 384 (16):1491-1502. [QxMD MEDLINE Link] . [Full Text] .

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet . 2021 May 1. 397 (10285):1637-1645. [QxMD MEDLINE Link] . [Full Text] .

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet . 2020 Feb 15. 395 (10223):473-475. [QxMD MEDLINE Link] .

[Guideline] Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M, Prescott HC, et al. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Crit Care Med . 2021 Mar 1. 49 (3):e219-e234. [QxMD MEDLINE Link] . [Full Text] .

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA . 2020 Sep 2. [QxMD MEDLINE Link] . [Full Text] .

Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic. JAMA . 2020 Sep 2. [QxMD MEDLINE Link] . [Full Text] .

Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol . 2022 Feb. 22 (2):77-84. [QxMD MEDLINE Link] . [Full Text] .

Carvelli J, Demaria O, Vély F, Batista L, Chouaki Benmansour N, Fares J, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature . 2020 Dec. 588 (7836):146-150. [QxMD MEDLINE Link] . [Full Text] .

Aiello S, Gastoldi S, Galbusera M, Ruggenenti P, Portalupi V, Rota S, et al. C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Adv . 2022 Jan 8. 6 (3):866-881. [QxMD MEDLINE Link] . [Full Text] .

Vlaar APJ, Witzenrath M, van Paassen P, and the, PANAMO study group. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med . 2022 Dec. 10 (12):1137-1146. [QxMD MEDLINE Link] . [Full Text] .

Strich JR, Tian X, Samour M, King CS, Shlobin O, Reger R, et al. Fostamatinib for the treatment of hospitalized adults with COVD-19 A randomized trial. Clin Infect Dis . 2021 Sep 1. [QxMD MEDLINE Link] . [Full Text] .

Reis G, Moreira Silva EAS, Medeiros Silva DC, and the, TOGETHER Investigators. Early Treatment with Pegylated Interferon Lambda for Covid-19. N Engl J Med . 2023 Feb 9. 388 (6):518-528. [QxMD MEDLINE Link] . [Full Text] .

Kalil AC, Mehta AK, Patterson TF, and the, ACTT-3 study group members. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med . 2021 Oct 18. [QxMD MEDLINE Link] . [Full Text] .

Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation . 2004 Jun 1. 109 (21 Suppl 1):II18-26. [QxMD MEDLINE Link] . [Full Text] .

Hariyanto TI, Kurniawan A. Statin therapy did not improved the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr . 2020 Aug 26. 14(6):1613-1615. [QxMD MEDLINE Link] . [Full Text] .

Kow CS, Hasan SS. Meta-analysis of Effect of Statins in Patients with COVID-19. Am J Cardiol . 2020 Aug 12. [QxMD MEDLINE Link] . [Full Text] .

Castiglione V, Chiriacò M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother . 2020 Jul 1. 6 (4):258-259. [QxMD MEDLINE Link] . [Full Text] .

Yao JS, Paguio JA, Dee EC, Tan HC, Moulick A, Milazzo C, et al. The minimal effect of zinc on the survival of hospitalized patients with Covid-19: an observational study. Chest . 2020 Jul 22. [QxMD MEDLINE Link] . [Full Text] .

Sahota O. Understanding vitamin D deficiency. Age Ageing . 2014 Sep. 43 (5):589-91. [QxMD MEDLINE Link] . [Full Text] .

Bishop CW, Ashfaq A, Melnick JZ, Vazquez-Escarpanter E, Fialkow JA, Strugnell SA, et al. Results from the REsCUe trial: a randomized controlled trial with extended-release calcifediol in symptomatic outpatients with COVID-19. medRXiv . 2022 Feb 05. [Full Text] .

Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw Open . 2023 Jan 3. 6 (1):e2250647. [QxMD MEDLINE Link] . [Full Text] .

Senefeld JW, Gorman EK, Johnson PW, et al. Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis. Mayo Clin Proc Innov Qual Outcomes . 2023 Oct. 7 (5):499-513. [QxMD MEDLINE Link] . [Full Text] .

Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF, McQuilten ZK, et al. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA . 2021 Oct 4. [QxMD MEDLINE Link] .

A Study to Investigate the Prevention of COVID-19 with VYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2. ClinicalTrials.gov. Available at https://classic.clinicaltrials.gov/ct2/show/NCT06039449 . 2024 January 18; Accessed: August 28, 2024.

Levin MJ, Ustianowski A, De Wit S, and the, PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med . 2022 Jun 9. 386 (23):2188-2200. [QxMD MEDLINE Link] . [Full Text] .

Young-Xu Y, Epstein L, Marconi VC, Davey V, Zwain G, Smith J, et al. Tixagevimab/cilagavimab for prevention of COVID-19 during the omicron surge: Retrospective analysis of national VA electronic data. medRxiv . 2022 May 29. [Full Text] .

Westendorf K, Žentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep . 2022 May 17. 39 (7):110812. [QxMD MEDLINE Link] . [Full Text] .

Gupta A, Gonzalez-Rojas Y, Juarez E, and the, COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med . 2021 Nov 18. 385 (21):1941-1950. [QxMD MEDLINE Link] . [Full Text] .

GSK and Vir submit emergency use authorization application to FDA for intramuscular administration of sotrovimab for the early treatment of COVID-19. GlaxoSmithKline . 2022 Jan 13. Available at https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-submit-emergency-use-authorization-application-to-fda-for-intramuscular-administration-of-sotrovimab-for-the-early-treatment-of-covid-19/ .

O'Brien MP, Forleo-Neto E, Musser BJ, and the, Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl J Med . 2021 Aug 4. [QxMD MEDLINE Link] . [Full Text] .

Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med . 2020 Dec 17. [QxMD MEDLINE Link] . [Full Text] .

RECOVERY Collaborative Group, Horby PW, Mafham M, Peto L, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. medRxiv . 2021 Jun 16. [Full Text] .

Dougan M, Nirula A, Azizad M, and the, BLAZE-1 Investigators. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N Engl J Med . 2021 Oct 7. 385 (15):1382-1392. [QxMD MEDLINE Link] . [Full Text] .

Cohen MS, Nirula A, Mulligan MJ, and the, BLAZE-2 Investigators. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. JAMA . 2021 Jul 6. 326 (1):46-55. [QxMD MEDLINE Link] . [Full Text] .

Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med . 2020 May 21. 382 (21):1969-1973. [QxMD MEDLINE Link] . [Full Text] .

Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines for COVID-19: The current state of play. Paediatr Respir Rev . 2020 Sep. 35:43-49. [QxMD MEDLINE Link] . [Full Text] .

Katneni UK, Alexaki A, Hunt RC, Schiller T, DiCuccio M, Buehler PW, et al. Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus. Thromb Haemost . 2020 Aug 24. [QxMD MEDLINE Link] . [Full Text] .

Ferguson J, Volk S, Vondracek T, Flanigan J, Chernaik A. Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: A retrospective cohort study. J Clin Pharmacol . 2020 Sep 3. [QxMD MEDLINE Link] . [Full Text] .

Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol . 2020 Jul 7. 76 (1):122-124. [QxMD MEDLINE Link] . [Full Text] .

NIH ACTIV-4B COVID-19 outpatient thrombosis prevention trial ends early. Brigham Health . 2021 Jun 22. Available at https://www.brighamandwomens.org/about-bwh/newsroom/press-releases-detail?id=3925 .

REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med . 2021 Aug 4. [QxMD MEDLINE Link] . [Full Text] .

ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med . 2021 Aug 4. [QxMD MEDLINE Link] . [Full Text] .

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN). ClinicalTrials.gov. Available at https://www.clinicaltrials.gov/ct2/show/NCT04655586 . 2021 Nov 03; Accessed: August 28, 2024.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature . 2020 Mar. 579 (7798):270-273. [QxMD MEDLINE Link] . [Full Text] .

Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Feldman A, D'Andréa Saba Arruda G, et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. Am Heart J . 2020 Aug. 226:49-59. [QxMD MEDLINE Link] . [Full Text] .

Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation . 2020 Mar 21. [QxMD MEDLINE Link] . [Full Text] .

Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med . 2005 Aug. 11 (8):875-9. [QxMD MEDLINE Link] . [Full Text] .

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon S. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med . 2020 March 30. [QxMD MEDLINE Link] . [Full Text] .

Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension . 2004 May. 43 (5):970-6. [QxMD MEDLINE Link] . [Full Text] .

Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation . 2005 May 24. 111 (20):2605-10. [QxMD MEDLINE Link] . [Full Text] .

Klimas J, Olvedy M, Ochodnicka-Mackovicova K, Kruzliak P, Cacanyiova S, Kristek F, et al. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med . 2015 Aug. 19 (8):1965-74. [QxMD MEDLINE Link] . [Full Text] .

Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. J Card Fail . 2020 May. 26 (5):370. [QxMD MEDLINE Link] . [Full Text] .

Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J . 2020 May 14. 41 (19):1810-1817. [QxMD MEDLINE Link] . [Full Text] .

Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, et al. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA Netw Open . 2021 Mar 1. 4 (3):e213594. [QxMD MEDLINE Link] . [Full Text] .

Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax . 2015 Oct. 70 (10):984-9. [QxMD MEDLINE Link] . [Full Text] .

Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev . 2020 Apr 15. [QxMD MEDLINE Link] . [Full Text] .

Muniyappa R, Gubbi S. COVID-19 Pandemic, Corona Viruses, and Diabetes Mellitus. Am J Physiol Endocrinol Metab . 2020 Mar 31. [QxMD MEDLINE Link] . [Full Text] .

DPP4 dipeptidyl peptidase 4. National Center for Biotechnology Information (NCBI). Available at https://www.ncbi.nlm.nih.gov/gene/1803 . 2020 Apr 20; Accessed: August 28, 2024.

Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnology & Biotechnological Equipment. 2020 . 2020. 34(1):469-74. [Full Text] .

Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency. Am J Trop Med Hyg . 2020 Apr 16. [QxMD MEDLINE Link] . [Full Text] .

López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA . 2021 Apr 13. 325 (14):1426-1435. [QxMD MEDLINE Link] . [Full Text] .

Lim SCL, Hor CP, Tay KH, and the, I-TECH Study Group. Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial. JAMA Intern Med . 2022 Feb 18. [QxMD MEDLINE Link] . [Full Text] .

Reis G, Silva EASM, Silva DCM, and the, TOGETHER Investigators. Effect of Early Treatment with Ivermectin among Patients with Covid-19. N Engl J Med . 2022 May 5. 386 (18):1721-1731. [QxMD MEDLINE Link] . [Full Text] .

Naggie S, Boulware DR, Lindsell CJ, for the, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA . 2022 Oct 25. 328 (16):1595-1603. [QxMD MEDLINE Link] . [Full Text] .

Naggie S, Boulware DR, Lindsell CJ, for the, Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. JAMA . 2023 Feb 20. [QxMD MEDLINE Link] . [Full Text] .

Bramante CT, Huling JD, Tignanelli CJ, for the COVID-OUT Trial Team. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Eng J Med . 2022. 387:599-610. [Full Text] .

Reis G, Dos Santos Moreira-Silva EA, Silva DCM, and the, TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health . 2022 Jan. 10 (1):e42-e51. [QxMD MEDLINE Link] . [Full Text] .

McCarthy MW, Naggie S, Boulware DR, and the, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA . 2023 Jan 24. 329 (4):296-305. [QxMD MEDLINE Link] .

Golan Y, Campos JAS, Woolson R, Cilla D, Hanabergh R, Gonzales-Rojas Y, et al. Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial. Clin Infect Dis . 2023 Feb 8. 76 (3):e10-e17. [QxMD MEDLINE Link] . [Full Text] .

Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med . 2012 May 17. 366 (20):1881-90. [QxMD MEDLINE Link] . [Full Text] .

Simpson TF, Kovacs RJ, Stecker EC. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. American College of Cardiology; Cardiology Magazine. Available at https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19 . 2020 Mar 29; Accessed: August 28, 2024.

[Guideline] Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation . 2020 Apr 8. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. Mayo Clin Proc . 2020 Apr 07. [Full Text] .

Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol . 2020 May 1. [QxMD MEDLINE Link] . [Full Text] .

Chorin E, Dai M, Shulman E, Wadhwani L, et al. The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin. medRxiv . 2020 Apr 03. [Full Text] .

Borba M, de Almeida Val F, Sampaio VS, Alexandre MA, Melo GC, Brito M, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). MedRxiv . 2020 Apr 11. [Full Text] .

Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv . 2020 Apr 10. [Full Text] .

Supady A, Weber E, Rieder M, Lother A, Niklaus T, Zahn T, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med . 2021 Jul. 9 (7):755-762. [QxMD MEDLINE Link] . [Full Text] .

Matson J, Lange P, Honore PM, Chung KK. Adverse outcomes with extracorporeal adsorbent blood treatments in toxic systemic inflammation: a perspective on possible mechanisms. Ann Intensive Care . 2022 Nov 12. 12 (1):105. [QxMD MEDLINE Link] . [Full Text] .

Zhang Q, et al. Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett . 2020 Jun 17. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Hayden MK, Hanson KE, Englund JA, Lee MJ, Loeb M, Lee F, et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing (December 2023). Clin Infect Dis . 2024 Jun 27. 78 (7):e385-e415. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Hayden MK, Hanson KE, Englund JA, et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023). Clin Infect Dis . 2024 Jun 27. 78 (7):e350-e384. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] CDC. Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/covid/hcp/clinical-care/clinical-specimen-guidelines.html . June 4, 2024; Accessed: August 24, 2024.

McFee DRB. COVID-19 Laboratory Testing/CDC Guidelines. Dis Mon . 2020 Sep. 66 (9):101067. [QxMD MEDLINE Link] . [Full Text] .

Potpara T, Angiolillo DJ, Bikdeli B, Capodanno D, Cole O, Yataco AC, et al. Antithrombotic Therapy in Arterial Thrombosis and Thromboembolism in COVID-19: An American College of Chest Physicians Expert Panel Report. Chest . 2023 Dec. 164 (6):1531-1550. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Schulman S, Arnold DM, Bradbury CA, et al. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost . 2024 Jun. 22 (6):1779-1797. [QxMD MEDLINE Link] . [Full Text] .

CDC. Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/covid/hcp/infection-control/guidance-risk-assesment-hcp.html . March 18, 2024; Accessed: August 27, 2024.

[Guideline] Center for Clinical Standards and Quality/Quality, Safety & Oversight Group. Guidance for Infection Control and Prevention Concerning Coronavirus Disease (COVID-19): FAQs and Considerations for Patient Triage, Placement and Hospital Discharge. Available at https://www.cms.gov/files/document/qso-20-13-hospitalspdf.pdf-2 . March 4, 2020; Accessed: August 28, 2024.

[Guideline] COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/ . 2021 Mar 05; Accessed: August 28, 2024.

Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College COVID-19 Response Team. Available at https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf . 2020 Mar 16; Accessed: August 28, 2024.

Christie A, Brooks JT, Hicks LA, et al. Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage. MMWR Morb Mortal Wkly Rep . 2021. 70:1044–1047. [Full Text] .

CDC. Underlying medical conditions associated with high risk for severe COVID-19: Information for healthcare providers. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html . 2021 Mar 29; last update July 30, 2024; Accessed: August 28, 2024.

CDC. Coronavirus Disease 2019 (COVID-19) – Cases in the U.S. Centers for Disease Control and Prevention (CDC). Available at https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days . 2023 Mar 29; Accessed: August 28, 2024.

Hillis SD, Blenkinsop A, Villaveces A, Annor FB, Liburd L, Massetti GM, et al. COVID-19-Associated Orphanhood and Caregiver Death in the United States. Pediatrics . 2021 Oct 7. [QxMD MEDLINE Link] . [Full Text] .

CDC. COVID Data Tracker. Centers for Disease Control and Prevention. Available at https://covid.cdc.gov/covid-data-tracker/#datatracker-home . May 11, 2023; Accessed: August 28, 2024.

Bixler D, Miller AD, Mattison CP, and the, Pediatric Mortality Investigation Team. SARS-CoV-2-Associated Deaths Among Persons Aged MMWR Morb Mortal Wkly Rep</i>. 2020 Sep 18. 69 (37):1324-1329. [QxMD MEDLINE Link] . [Full Text] .

Chao JY, Derespina KR, Herold BC, Goldman DL, Aldrich M, Weingarten J, et al. Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City. J Pediatr . 2020 Aug. 223:14-19.e2. [QxMD MEDLINE Link] . [Full Text] .

Han MS, Choi EH, Chang SH, Jin BL, Lee EJ, Kim BN, et al. Clinical Characteristics and Viral RNA Detection in Children With Coronavirus Disease 2019 in the Republic of Korea. JAMA Pediatr . 2020 Aug 28. [QxMD MEDLINE Link] . [Full Text] .

Pierce-Williams RAM, Burd J, Felder L, Khoury R, Bernstein PS, Avila K, et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. Am J Obstet Gynecol MFM . 2020 Aug. 2 (3):100134. [QxMD MEDLINE Link] . [Full Text] .

Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. JAMA . 2020 Dec 8. 324 (22):2251-2252. [QxMD MEDLINE Link] . [Full Text] .

McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circ Res . 2020 Jul 31. 127 (4):571-587. [QxMD MEDLINE Link] . [Full Text] .

Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J . 2021 Feb 18. [QxMD MEDLINE Link] . [Full Text] .

Pérez-Lago L, Kestler M, Sola-Campoy PJ, et al. SARS-CoV-2 superinfection and reinfection with three different strains. Transbound Emerg Dis . 2021 Oct 23. [QxMD MEDLINE Link] .

Harrington DP, Baden LR, Hogan JW. A Large, Simple Trial Leading to Complex Questions. N Engl J Med . 2020 Dec 2. [QxMD MEDLINE Link] . [Full Text] .

Ader F, Bouscambert-Duchamp M, Hites M, and the, DisCoVeRy Study Group. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis . 2021 Sep 14. [QxMD MEDLINE Link] . [Full Text] .

Guimarães PO, Quirk D, Furtado RH, and the STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med . 2021 Jun 16. [QxMD MEDLINE Link] . [Full Text] .

Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med . 2021 Apr 22. 384 (16):1503-1516. [QxMD MEDLINE Link] . [Full Text] .

Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. JAMA Netw Open . 2020 Sep 1. 3 (9):e2019722. [QxMD MEDLINE Link] . [Full Text] .

Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of Coronavirus Disease 2019. Crit Care Med . 2020 Sep. 48 (9):1358-1364. [QxMD MEDLINE Link] . [Full Text] .

Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace . 2017 Aug 1. 19 (8):1280-1287. [QxMD MEDLINE Link] . [Full Text] .

Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond) . 2012 Dec. 123 (11):649-58. [QxMD MEDLINE Link] .

RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. The Lancet . 2020 Oct 05. [Full Text] .

[Guideline] Centers for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19). CDC. Available at https://www.cdc.gov/covid/hcp/clinical-care/clinical-specimen-guidelines.html . 2020 Nov 05; Accessed: August 28, 2024.

[Guideline] AAP. FAQs: Management of Infants Born to Mothers with Suspected or Confirmed COVID-19. American Academy of Pediatrics. Available at https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/faqs-management-of-infants-born-to-covid-19-mothers/ . May 21, 2020; Accessed: August 28, 2024.

[Guideline] Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report. Chest . 2020 Jun 2. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost . 2020 May. 18 (5):1023-1026. [QxMD MEDLINE Link] . [Full Text] .

World Health Organization. Roadmap to improve and ensure good indoor ventilation in COVID-19 context (1 March 2021). World Health Organization. Available at https://www.who.int/publications/i/item/9789240021280 . March 1, 2021; Accessed: August 28, 2024.

Lim EHT, Vlaar APJ, Bos LDJ, and the, Amsterdam UMC COVID-19 Biobank Investigators. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the  phase 2 PANAMO trial. Respir Res . 2022 Dec 24. 23 (1):375. [QxMD MEDLINE Link] . [Full Text] .

Management Strategies in Children and Adolescents with Mild to Moderate COVID-19. American Academy of Pediatri cs. Available at https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/outpatient-covid-19-management-strategies-in-children-and-adolescents/ . Updated February 8, 2023; Accessed: August 28, 2024.

Huang YH, Kuo HC. Kawasaki Disease, MIS-C and COVID-19. Children (Basel) . 2023 Sep 22. 10 (10): [QxMD MEDLINE Link] . [Full Text] .

Simbar M, Nazarpour S, Sheidaei A. Evaluation of pregnancy outcomes in mothers with COVID-19 infection: a systematic review and meta-analysis. J Obstet Gynaecol . 2023 Dec. 43 (1):2162867. [QxMD MEDLINE Link] .

Rojas-Suarez J, Miranda J. Coronavirus Disease-2019 in Pregnancy. Clin Chest Med . 2023 Jun. 44 (2):373-384. [QxMD MEDLINE Link] .

He YF, Liu JQ, Hu XD, Li HM, Wu N, Wang J, et al. Breastfeeding vs. breast milk transmission during COVID-19 pandemic, which is more important?. Front Pediatr . 2023. 11:1253333. [QxMD MEDLINE Link] . [Full Text] .

Weiss A, Donnachie E, Beyerlein A, Ziegler AG, Bonifacio E. Type 1 Diabetes Incidence and Risk in Children With a Diagnosis of COVID-19. JAMA . 2023 Jun 20. 329 (23):2089-2091. [QxMD MEDLINE Link] .

Lippi G, Sanchis-Gomar F, Henry BM. COVID-19 and its long-term sequelae: what do we know in 2023?. Pol Arch Intern Med . 2023. 133: [Full Text] .

Brolly J, Chadwick DR. COVID-19 infection in people living with HIV. Br Med Bull . 2023 Sep 12. 147 (1):20-30. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, et al. Vaccination of Adults With Cancer: ASCO Guideline. J Clin Oncol . 2024 May 10. 42 (14):1699-1721. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Willis ZI, Oliveira CR, Abzug MJ, et al. Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce. J Pediatric Infect Dis Soc . 2024 Mar 19. 13 (3):159-185. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Biney IN, Ari A, Barjaktarevic IZ, et al. Guidance on Mitigating the Risk of Transmitting Respiratory Infections During Nebulization by the COPD Foundation Nebulizer Consortium. Chest . 2024 Mar. 165 (3):653-668. [QxMD MEDLINE Link] . [Full Text] .

Varshney K, Pillay P, Mustafa AD, Shen D, Adalbert JR, Mahmood MQ. A systematic review of the clinical characteristics of influenza-COVID-19 co-infection. Clin Exp Med . 2023 Nov. 23 (7):3265-3275. [QxMD MEDLINE Link] . [Full Text] .

Marjenberg Z, Leng S, Tascini C, Garg M, Misso K, El Guerche Seblain C, et al. Risk of long COVID main symptoms after SARS-CoV-2 infection: a systematic review and meta-analysis. Sci Rep . 2023 Sep 15. 13 (1):15332. [QxMD MEDLINE Link] . [Full Text] .

COVID-19 Forecasting Team. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet . 2023 Mar 11. 401 (10379):833-842. [QxMD MEDLINE Link] . [Full Text] .

CDC. About Reinfection. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/covid/about/reinfection.html . June 14, 2024; Accessed: August 26, 2024.

Reis S, Metzendorf MI, Kuehn R, Popp M, Gagyor I, Kranke P, et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database Syst Rev . 2023 Nov 30. 11 (11):CD015395. [QxMD MEDLINE Link] . [Full Text] .

Chen C, Fang J, Chen S, Rajaofera MJN, Li X, Wang B, et al. The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis. BMC Infect Dis . 2023 Oct 9. 23 (1):672. [QxMD MEDLINE Link] . [Full Text] .

CDC. Infection Control Guidance: SARS-CoV-2. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/covid/hcp/infection-control/index.html . June 24, 2024; Accessed: August 27, 2024.

CDC. SARS-CoV-2 Specimens: Packing and Shipping. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/covid/media/pdfs/COVID-19-Pack-and-Ship-Job-Aid-508.pdf . No date on document; Accessed: August 27, 2024.

CDC. Clinical Overview of Long COVID. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/covid/hcp/clinical-overview/index.html . July 12, 2024; Accessed: August 27, 2024.

Zhang J, Ejikemeuwa A, Gerzanich V, et al. Understanding the Role of SARS-CoV-2 ORF3a in Viral Pathogenesis and COVID-19. Front Microbiol . 2022. 13:854567. [QxMD MEDLINE Link] . [Full Text] .

Bonnet B, Cosme J, Dupuis C, Coupez E, Adda M, Calvet L, et al. Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation. EBioMedicine . 2021 Nov. 73:103622. [QxMD MEDLINE Link] . [Full Text] .

Yang KS, Leeuwon SZ, Xu S, Liu WR. Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir. J Med Chem . 2022 Jul 14. 65 (13):8686-8698. [QxMD MEDLINE Link] . [Full Text] .

FAQs: Management of Infants Born to Mothers with Suspected or Confirmed COVID-19. American Academy of Pediatrics. Available at https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/faqs-management-of-infants-born-to-covid-19-mothers/ . November 10, 2022; Accessed: August 29, 2024.

Ko SH, Radecki P, Belinky F, Bhiman JN, Meiring S, Kleynhans J, et al. Rapid intra-host diversification and evolution of SARS-CoV-2 in advanced HIV infection. Nat Commun . 2024 Aug 22. 15 (1):7240. [QxMD MEDLINE Link] . [Full Text] .

Bellia C, Andreadi A, D'Ippolito I, Scola L, Barraco S, Meloni M, et al. Prevalence and risk of new-onset diabetes mellitus after COVID-19: a systematic review and meta-analysis. Front Endocrinol (Lausanne) . 2023. 14:1215879. [QxMD MEDLINE Link] . [Full Text] .

• The heart is normal in size. There are diffuse, patchy opacities throughout both lungs, which may represent multifocal viral/bacterial pneumonia versus pulmonary edema. These opacities are particularly confluent along the periphery of the right lung. There is left midlung platelike atelectasis. Obscuration of the left costophrenic angle may represent consolidation versus a pleural effusion with atelectasis. There is no pneumothorax.
• The heart is normal in size. There are bilateral hazy opacities, with lower lobe predominance. These findings are consistent with multifocal/viral pneumonia. No pleural effusion or pneumothorax are seen.
• The heart is normal in size. Patchy opacities are seen throughout the lung fields. Patchy areas of consolidation at the right lung base partially silhouettes the right diaphragm. There is no effusion or pneumothorax. Degenerative changes of the thoracic spine are noted.
• The same patient as above 10 days later.
• The trachea is in midline. The cardiomediastinal silhouette is normal in size. There are diffuse hazy reticulonodular opacities in both lungs. Differential diagnoses include viral pneumonia, multifocal bacterial pneumonia or ARDS. There is no pleural effusion or pneumothorax.
• Axial chest CT demonstrates patchy ground-glass opacities with peripheral distribution.
• Coronal reconstruction chest CT of the same patient above, showing patchy ground-glass opacities.
• Axial chest CT shows bilateral patchy consolidations (arrows), some with peripheral ground-glass opacity. Findings are in peripheral and subpleural distribution.
• Table 1. SARS-CoV-2 Monoclonal Antibodies – inactive EUAs

Contributor Information and Disclosures

David J Cennimo, MD, FAAP, FACP, FIDSA, AAHIVS Associate Professor of Medicine and Pediatrics, Adult and Pediatric Infectious Diseases, Rutgers New Jersey Medical School David J Cennimo, MD, FAAP, FACP, FIDSA, AAHIVS is a member of the following medical societies: American Academy of HIV Medicine , American Academy of Pediatrics , American College of Physicians , American Medical Association , HIV Medicine Association , Infectious Diseases Society of America , Medical Society of New Jersey , Pediatric Infectious Diseases Society Disclosure: Nothing to disclose.

Scott J Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP Antimicrobial Stewardship Program Coordinator, Infectious Diseases Pharmacy Residency Program Director, Department of Pharmaceutical and Nutrition Care, Division of Infectious Diseases, Nebraska Medicine; Clinical Associate Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center Scott J Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP is a member of the following medical societies: American Association of Colleges of Pharmacy , American College of Clinical Pharmacy , American Pharmacists Association , American Society for Microbiology , American Society of Health-System Pharmacists , Infectious Diseases Society of America , Society of Infectious Diseases Pharmacists Disclosure: Received research grant from: Merck & Co., Inc.

Keith M Olsen, PharmD, FCCP, FCCM Dean and Professor, College of Pharmacy, University of Nebraska Medical Center Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference Disclosure: Nothing to disclose.

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha , American College of Physicians , American Medical Association , Association of Professors of Medicine , Infectious Diseases Society of America , Oklahoma State Medical Association , Southern Society for Clinical Investigation Disclosure: Nothing to disclose.

Molly Marie Miller, PharmD Clinical Infectious Diseases Pharmacist Practitioner, Nebraska Medicine Molly Marie Miller, PharmD is a member of the following medical societies: Society of Infectious Diseases Pharmacists Disclosure: Nothing to disclose.

What would you like to print?

• Print this section
• Print the entire contents of
• Print the entire contents of article

• COVID-19 Variants
• COVID-19 Pulmonary Management
• Long Coronavirus 2019 (COVID-19)
• Symptoms and Management of Coronavirus Disease 2019 (COVID-19) FAQ
• Coronavirus Disease 2019 (COVID-19)
• Diagnostics for Coronavirus Disease 2019 (COVID-19) Patients
• COVID-19 Treatment: Investigational Drugs and Other Therapies
• Picture of COVID-19 in Europe Is Complex
• Sleep Disturbances Increase Susceptibility to COVID-19
• Global Consensus Reached on COVID-19 Vaccine Updates

• Drug Interaction Checker
• Pill Identifier
• Calculators

• 2010comirnaty-covid-19-vaccine-mRNA-pfizer-4000140Drugs Drugs COVID-19 vaccine, mRNA-Pfizer

• 2010covid-19-vaccine-adjuvanted-novavax-4000146Drugs Drugs COVID-19 vaccine, adjuvanted-Novavax
• 2010spikevax-covid-19-vaccine-mRNA-moderna-4000149Drugs Drugs COVID-19 vaccine, mRNA-Moderna